US20220160869A1 - Vaccines for use in treating various diseases and disorders - Google Patents
Vaccines for use in treating various diseases and disorders Download PDFInfo
- Publication number
- US20220160869A1 US20220160869A1 US17/544,636 US202117544636A US2022160869A1 US 20220160869 A1 US20220160869 A1 US 20220160869A1 US 202117544636 A US202117544636 A US 202117544636A US 2022160869 A1 US2022160869 A1 US 2022160869A1
- Authority
- US
- United States
- Prior art keywords
- age
- antigen
- vaccine
- protein
- apo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 52
- 208000037765 diseases and disorders Diseases 0.000 title abstract description 3
- 239000000427 antigen Substances 0.000 claims abstract description 68
- 108091007433 antigens Proteins 0.000 claims abstract description 68
- 102000036639 antigens Human genes 0.000 claims abstract description 68
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 63
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 26
- 239000002671 adjuvant Substances 0.000 claims abstract description 24
- 230000010094 cellular senescence Effects 0.000 claims abstract description 19
- 230000003053 immunization Effects 0.000 claims abstract description 9
- 239000003755 preservative agent Substances 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 94
- 208000001076 sarcopenia Diseases 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 32
- 208000035475 disorder Diseases 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 16
- 108010052285 Membrane Proteins Proteins 0.000 claims description 11
- 210000000577 adipose tissue Anatomy 0.000 claims description 11
- 102000014914 Carrier Proteins Human genes 0.000 claims description 9
- 108010078791 Carrier Proteins Proteins 0.000 claims description 9
- 101710088194 Dehydrogenase Proteins 0.000 claims description 8
- 102000018697 Membrane Proteins Human genes 0.000 claims description 8
- 108010071390 Serum Albumin Proteins 0.000 claims description 8
- 102000007562 Serum Albumin Human genes 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 claims description 7
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 7
- 241000282412 Homo Species 0.000 claims description 7
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 7
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 6
- 241000283707 Capra Species 0.000 claims description 6
- 241001494479 Pecora Species 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 208000002177 Cataract Diseases 0.000 claims description 5
- 102000001554 Hemoglobins Human genes 0.000 claims description 5
- 108010054147 Hemoglobins Proteins 0.000 claims description 5
- 108090001030 Lipoproteins Proteins 0.000 claims description 5
- 102000004895 Lipoproteins Human genes 0.000 claims description 5
- 210000000987 immune system Anatomy 0.000 claims description 5
- 239000002753 trypsin inhibitor Substances 0.000 claims description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- 241000283086 Equidae Species 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 4
- 238000008416 Ferritin Methods 0.000 claims description 4
- 102000004867 Hydro-Lyases Human genes 0.000 claims description 4
- 108090001042 Hydro-Lyases Proteins 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 102000005890 Spectrin Human genes 0.000 claims description 4
- 108010019965 Spectrin Proteins 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229960005348 antithrombin iii Drugs 0.000 claims description 4
- 210000000170 cell membrane Anatomy 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 229950003499 fibrin Drugs 0.000 claims description 4
- 229940012952 fibrinogen Drugs 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 229960000274 lysozyme Drugs 0.000 claims description 4
- 239000004325 lysozyme Substances 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 229940127126 plasminogen activator Drugs 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000005495 thyroid hormone Substances 0.000 claims description 4
- 229940036555 thyroid hormone Drugs 0.000 claims description 4
- 239000012581 transferrin Substances 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- VTYFITADLSVOAS-NSHDSACASA-N 1-(L-norleucin-6-yl)pyrraline Chemical compound OC(=O)[C@@H](N)CCCCN1C(CO)=CC=C1C=O VTYFITADLSVOAS-NSHDSACASA-N 0.000 claims description 3
- 108010053481 Antifreeze Proteins Proteins 0.000 claims description 3
- 230000001668 ameliorated effect Effects 0.000 claims description 3
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 claims description 3
- UENLDOJJKXLRJI-ZETCQYMHSA-N (2s)-6-amino-2-(2-carboxyethylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NCCC(O)=O UENLDOJJKXLRJI-ZETCQYMHSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- NDDZLVOCGALPLR-GNSUAQHMSA-N docosanoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 NDDZLVOCGALPLR-GNSUAQHMSA-N 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 102000005548 Hexokinase Human genes 0.000 claims 3
- 108700040460 Hexokinases Proteins 0.000 claims 3
- 241000237988 Patellidae Species 0.000 claims 3
- 108060003552 hemocyanin Proteins 0.000 claims 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 53
- 235000018102 proteins Nutrition 0.000 description 51
- 210000003205 muscle Anatomy 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 21
- 238000011282 treatment Methods 0.000 description 21
- 230000009758 senescence Effects 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 18
- 230000032683 aging Effects 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 12
- 208000024827 Alzheimer disease Diseases 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 8
- NUXSIDPKKIEIMI-LURJTMIESA-N N(6)-carboxymethyl-L-lysine Chemical compound OC(=O)[C@@H](N)CCCCNCC(O)=O NUXSIDPKKIEIMI-LURJTMIESA-N 0.000 description 8
- 210000001130 astrocyte Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 208000018737 Parkinson disease Diseases 0.000 description 7
- 208000024777 Prion disease Diseases 0.000 description 7
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 230000036252 glycation Effects 0.000 description 7
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 6
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 5
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 230000005021 gait Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000002025 microglial effect Effects 0.000 description 5
- 230000004220 muscle function Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 102000029797 Prion Human genes 0.000 description 4
- 108091000054 Prion Proteins 0.000 description 4
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 210000003098 myoblast Anatomy 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000036314 physical performance Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000009829 Lewy Body Disease Diseases 0.000 description 3
- 201000002832 Lewy body dementia Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 102100026882 Alpha-synuclein Human genes 0.000 description 2
- 238000003691 Amadori rearrangement reaction Methods 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 2
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 2
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 2
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 2
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 2
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 2
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 108090000185 alpha-Synuclein Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000011871 bio-impedance analysis Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000017580 chronic wasting disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 2
- 201000006061 fatal familial insomnia Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 229960004279 formaldehyde Drugs 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 206010023497 kuru Diseases 0.000 description 2
- 210000004558 lewy body Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940124272 protein stabilizer Drugs 0.000 description 2
- -1 protein stabilizers Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000028617 response to DNA damage stimulus Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 208000008864 scrapie Diseases 0.000 description 2
- 239000000849 selective androgen receptor modulator Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FJIGLGLZNXQEDE-GDVGLLTNSA-N (2s)-2,6-diaminooctanedioic acid Chemical compound OC(=O)CC(N)CCC[C@H](N)C(O)=O FJIGLGLZNXQEDE-GDVGLLTNSA-N 0.000 description 1
- AAQFSZFQCXLMNT-ACMTZBLWSA-N (3s)-3-amino-4-[[(2s)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid;hydrochloride Chemical compound Cl.OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 AAQFSZFQCXLMNT-ACMTZBLWSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- KHJWSKNOMFJTDN-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KHJWSKNOMFJTDN-UHFFFAOYSA-N 0.000 description 1
- NUXSIDPKKIEIMI-UHFFFAOYSA-N 2-azaniumyl-6-(carboxylatomethylazaniumyl)hexanoate Chemical compound OC(=O)C(N)CCCCNCC(O)=O NUXSIDPKKIEIMI-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Polymers CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- 101000664887 Homo sapiens Superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100263236 Mus musculus Uts2 gene Proteins 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical class O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102100033504 Thyroglobulin Human genes 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 101150026065 UCN2 gene Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000005630 Urocortins Human genes 0.000 description 1
- 108010059705 Urocortins Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011872 anthropometric measurement Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229910001593 boehmite Inorganic materials 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 108010004903 glycosylated serum albumin Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 102000056070 human SOD1 Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007991 neuronal integrity Effects 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 102200078754 rs863223435 Human genes 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 101150062190 sod1 gene Proteins 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940038774 squalene oil Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000000777 urocortin Substances 0.000 description 1
- ZEBBPGHOLWPSGI-KPLDDXDLSA-N urocortin ii Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CS)C(N)=O)CC1=CN=CN1 ZEBBPGHOLWPSGI-KPLDDXDLSA-N 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- Sarcopenia is the loss of muscle mass, quality and strength associated with aging. Humans begin to lose muscle mass and function at some point in the third decade of life. This loss of muscle mass typically accelerates around age 75. Sarcopenia develops in both physically active and physically inactive people. As the average human lifespan continues to increase, sarcopenia is becoming a significant health concern. The loss of muscle mass from sarcopenia may lead to poor balance, reduced gait speed and frailty. Individuals suffering from sarcopenia are more susceptible to injury and disability, and may be unable to live independently as a result. The spread of sarcopenia will likely result in increases in health care and assisted living expenses.
- sarcopenia has been considered to be an inevitable result of aging and the natural deterioration of the body over time.
- the primary treatment for sarcopenia is exercise. Physical exercise, particularly resistance training or strength training, can reduce the impact of sarcopenia.
- Testosterone, anabolic steroids, ghrelin, vitamin D, angiotensin converting enzyme inhibitors (ACE inhibitors), eicosapentaenoic acid (EPA), myostatin, selective androgen receptor modulators (SARMs), urocortin II (Ucn2) and hormone replacement therapy have been investigated or are being studied as potential treatments for sarcopenia.
- ACE inhibitors angiotensin converting enzyme inhibitors
- EPA eicosapentaenoic acid
- SARMs selective androgen receptor modulators
- Ucn2 urocortin II
- FDA U.S. Food and Drug Administration
- Senescent cells are cells that are partially-functional or non-functional and are in a state of irreversible proliferative arrest. Senescence is a distinct state of a cell, and is associated with biomarkers, such as activation of the biomarker p16 ink4a , and expression of ⁇ -galactosidase. Senescence begins with damage or stress (such as overstimulation by growth factors) of cells.
- AGEs Advanced glycation end-products
- AGEs also referred to AGE-modified proteins, or glycation end-products
- AGEs arise from a non-enzymatic reaction of sugars with protein side-chains in aging cells
- Ando, K. et al. Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products during Aging in the Circulation, Biochem Biophys Res Commun ., Vol. 258, 123, 125 (1999)
- This process begins with a reversible reaction between the reducing sugar and the amino group to form a Schiff base, which proceeds to form a covalently-bonded Amadori rearrangement product.
- AGEs may also be formed from other processes.
- the advanced glycation end product, N ⁇ -(carboxymethyl)lysine is a product of both lipid peroxidation and glycoxidation reactions.
- AGEs have been associated with several pathological conditions including diabetic complications, inflammation, retinopathy, nephropathy, atherosclerosis, stroke, endothelial cell dysfunction, and neurodegenerative disorders (Bierhaus A, “AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept,” Cardiovasc Res, Vol. 37(3), 586-600 (1998)).
- AGE-modified proteins are also a marker of senescent cells. This association between glycation end-product and senescence is well known in the art. See, for example, Gruber, L. (WO 2009/143411, 26 Nov. 2009), Ando, K. et al. (Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products during Aging in the Circulation, Biochem Biophys Res Commun., Vol. 258, 123, 125 (1999)), Ahmed, E.K. et al. (“Protein Modification and Replicative Senescence of WI-38 Human Embryonic Fibroblasts” Aging Cells , vol. 9, 252, 260 (2010)), Vlassara, H.
- glycation end-products are “one of the major causes of spontaneous damage to cellular and extracellular proteins” (Ahmed, E.K. et al., see above, page 353). Accordingly, the accumulation of glycation end-products is associated with senescence and lack of function.
- AD Alzheimer's disease
- MS multiple sclerosis
- microglia and macrophages are shifted toward a strongly proinflammatory phenotype, reminiscent of SASP, and may potentiate neuronal damage by releasing proinflammatory cytokines and molecules (Luessi, F., et aL “Neurodegeneration in multiple sclerosis: novel treatment strategies” Expert Rev. Neurother., Vol 9, pp.1061-1077 (2012)).
- Satellite cells also known as myosatellite cells, present in the muscle tissue of ALS patients exhibit an abnormal senescent-like morphology, although they may be capable of proliferating in vitro (Pradat, P.-F. et al., “Abnormalities of satellite cells function in amyotrophic lateral sclerosis” Amyotrophic Lateral Sclerosis , Vol. 12, pp. 264-271 (2011)). Satellite cells are small multipotent cells found in mature muscle, which are able to give rise to additional satellite cells, or differentiate into myoblasts as well as provide additional myonuclei.
- Myoblasts are precursor cells which differentiate into myocytes (also referred to as muscle cells).
- a characteristic of PD and Lewy body dementia is the formation of Lewy bodies that form inside nerve cells.
- the primary structural component of the Lewy bodies is alpha-synuclein protein, in the form of fibrils.
- the presence of tangles and plaques are a characteristic of AD, the presence of which is used to definitively diagnose the condition.
- Plaques, composed of beta-amyloid protein also referred to as amyloid beta, A ⁇ or Abeta
- Prion diseases also known as transmissible spongiform encephalopathies (TSEs)
- TSEs transmissible spongiform encephalopathies
- Prion protein is a misfolded protein molecule which may propagate by transmitting a misfolded protein state, resulting in the accumulation of the misfolded protein and causing tissue damage and cell death (Dobson, D.
- SOD1 superoxide dismutase-1
- MG methyl glyoxal
- Damage or stress to mitochondrial DNA also sets off a DNA damage response which induces the cell to produce cell cycle blocking proteins. These blocking proteins prevent the cell from dividing. Continued damage or stress causes mTOR production, which in turn activates protein synthesis and inactivates protein breakdown. Further stimulation of the cells leads to programmed cell death (apoptosis).
- p16 is a protein involved in regulation of the cell cycle, by inhibiting the S phase. It can be activated during ageing or in response to various stresses, such as DNA damage, oxidative stress or exposure to drugs. p16 is typically considered a tumor suppressor protein, causing a cell to become senescent in response to DNA damage and irreversibly preventing the cell from entering a hyperproliferative state.
- Senescent cells are also known to fuel the growth of cancer cells. Senescent cells are associated with secretion of many factors involved in intercellular signaling, including pro-inflammatory factors; secretion of these factors has been termed the senescence-associated secretory phenotype, or SASP.
- SASP senescence-associated secretory phenotype
- Vaccines have been widely used since their introduction by Edward Jenner in the 1770s to confer immunity against a wide range of diseases and afflictions.
- Vaccine preparations contain a selected immunogenic agent capable of stimulating immunity to an antigen.
- antigens are used as the immunogenic agent in vaccines, such as, for example, viruses, either killed or attenuated, and purified viral components.
- Antigens used in the production of cancer vaccines include, for example, tumor-associated carbohydrate antigens (TACAs), dendritic cells, whole cells and viral vectors. Different techniques are employed to produce the desired amount and type of antigen being sought. For example, pathogenic viruses are grown either in eggs or cells. Recombinant DNA technology is often utilized to generate attenuated viruses for vaccines.
- Immunity is a long-term immune response, either cellular or humoral.
- a cellular immune response is activated when an antigen is presented, preferably with a co-stimulator to a T-cell which causes it to differentiate and produce cytokines.
- the cells involved in the generation of the cellular immune response are two classes of T-helper (Th) cells, Th1 and Th2.
- Th1 cells stimulate B cells to produce predominantly antibodies of the IgG2A isotype, which activates the complement cascade and binds the Fc receptors of macrophages
- Th2 cells stimulate B cells to produce IgG1 isotype antibodies in mice, IgG4 isotype antibodies in humans, and IgE isotype antibodies.
- the human body also contains “professional” antigen-presenting cells such as dendritic cells, macrophages, and B cells.
- a humoral immune response is triggered when a B cell selectively binds to an antigen and begins to proliferate, leading to the production of a clonal population of cells that produce antibodies that specifically recognize that antigen and which may differentiate into antibody-secreting cells, referred to as plasma-cells or memory-B cells.
- Antibodies are molecules produced by B-cells that bind a specific antigen.
- the antigen-antibody complex triggers several responses, either cell-mediated, for example by natural killers (NK) or macrophages, or serum-mediated, for example by activating the complement system, a complex of several serum proteins that act sequentially in a cascade that result in the lysis of the target cell.
- Immunological adjuvants are the component(s) of a vaccine which augment the immune response to the immunogenic agent.
- Adjuvants function by attracting macrophages to the immunogenic agent and then presenting the agent to the regional lymph nodes to initiate an effective antigenic response.
- Adjuvants may also act as carriers themselves for the immunogenic agent.
- Adjuvants may induce an inflammatory response, which may play an important role in initiating the immune response.
- Adjuvants include mineral compounds such as aluminum salts, oil emulsions, bacterial products, liposomes, immunostimulating complexes and squalene.
- vaccines include pharmaceutically acceptable excipients, preservatives, diluents and pH adjusters.
- a variety of these components of vaccines, as well as adjuvants, are described in www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf and Vogel, F. R. et aL, “A compendium of vaccine adjuvants and excipients”, Pharmaceutical Biotechnology , Vol. 6, pp. 141-228 (1995).
- Vaccines may therefore be used to stimulate the production of antibodies in the body and provide immunity against antigens.
- the immune system may destroy or remove cells that express the antigen.
- the invention is a method of treating or preventing a disease or disorder associated with cellular senescence comprising immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell.
- the invention is a method of treating a subject with a disease or disorder associated with cellular senescence comprising administering a first vaccine comprising a first AGE antigen and administering a second vaccine comprising a second AGE antigen.
- the second AGE antigen is different from the first AGE antigen.
- the invention is use of an AGE antigen for the manufacture of a medicament for treating or preventing a disease or disorder associated with cellular senescence.
- the invention is a composition comprising an AGE antigen for use in treating or preventing a disease or disorder associated with cellular senescence.
- the invention is a composition comprising an AGE antigen for use in treating sarcopenia.
- the invention is a composition comprising an AGE antigen for use in promoting tissue or organ regeneration.
- the invention is a composition comprising an AGE antigen for use in promoting regenerative processes or overcoming aging effects.
- the invention is a composition comprising an AGE antigen for use in treating atherosclerosis.
- the invention is a composition comprising an AGE antigen for use in preventing or delaying the onset of cataracts.
- the invention is a composition comprising an AGE antigen for use in preventing or delaying the onset of loss of adipose tissue.
- the invention is a composition comprising an AGE antigen for use in preventing or delaying the onset of lordokyphosis.
- the invention is a composition comprising an AGE antigen for use in treating inflammation or auto-immune disorders.
- the invention is a composition comprising an AGE antigen for use in treating neurodegenerative disorders.
- the invention is a composition comprising an AGE antigen for use in treating cancer or cancer metastases.
- the invention is a composition comprising an AGE antigen for use in increasing health span.
- the invention is a method of reducing the number of AGE-modified cells in a patient, comprising administering a vaccine comprising an AGE antigen.
- peptide means a molecule composed of 2-50 amino acids.
- protein means a molecule composed of more than 50 amino acids.
- muscle mass means the syndrome characterized by the presence of (1) low muscle mass and (2) low muscle function (low muscle strength or reduced physical performance).
- Muscle mass may be measured by body imaging techniques, such as computed tomography scanning (CT scan), magnetic resonance imaging (MRI) or dual energy X-ray absorptiometry (DXA or DEXA); bioimpedance analysis (BIA); body potassium measurement, such as total body potassium (TBK) or partial body potassium (PBK); or anthropometric measurements, such as mid-upper arm circumference, skin fold thickness or calf circumference.
- CT scan computed tomography scanning
- MRI magnetic resonance imaging
- DEXA dual energy X-ray absorptiometry
- BIOA bioimpedance analysis
- body potassium measurement such as total body potassium (TBK) or partial body potassium (PBK)
- anthropometric measurements such as mid-upper arm circumference, skin fold thickness or calf circumference.
- muscle mass is measured by CT scan, MRI or DXA.
- Muscle strength may
- muscle strength is measured by handgrip strength.
- Physical performance may be measured by the Short Physical Performance Battery, gait speed measurement, timed get-up-and-go (TGUG) or the stair climb power test.
- physical performance is measured by gait speed measurement.
- a subject may be identified as having sarcopenia or in need of treatment if (1) the subject is at least 25 years old and (2) his or her measured muscle mass and measured muscle function are two standard deviations or more below the mean value for healthy 25 year olds of the same gender and no alternative pathology has been identified to account for the reduced muscle mass and reduced muscle function.
- a subject being treated for sarcopenia is at least 40 years old.
- a subject being treated for sarcopenia is at least 50 years old. Most preferably, a subject being treated for sarcopenia is at least 60 years old.
- a subject may be identified as having sarcopenia or in need of treatment if (1) his or her gait speed is less than 1.0 m/s across a 4 m course and (2) he or she has an objectively measured low muscle mass, such as, for example, an appendicular mass relative to the square of height less than or equal to 7.23 kg/m 2 for male subjects or less than or equal to 5.67 kg/m 2 for female subjects (Fielding, R. A., et al., “Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences”, Journal of the American Medical Directors Association , Vol. 12(4), pp. 249-256 (May 2011).
- neurodegenerative disorder means disorders which result in neurons loosing function and/or dying, in the central nervous system including the brain.
- disorders included central nervous system neurodegenerative disorders such as AD, PD, Lewy body dementia, MS, prion diseases (also known as transmissible spongiform encephalopathies (TSEs), including Creutzfeldt-Jakob disease, variant Creutzfeldt-Jakob disease, bovine spongiform encephalopathy (“mad cow” disease), scrapie (in sheep and goats), chronic wasting disease (in deer and elk), kuru and fatal familial insomnia), and ALS.
- TSEs transmissible spongiform encephalopathies
- Neurodegenerative proteins are proteins which accumulate in a patient having a neurodegenerative disorders and which are associated with the neurodegenerative disorder. Examples include, beta-amyloid protein plaques (associated with AD), tau protein tangles (associated with AD), mutated superoxide dismutase-1 (associated with ALS), prion protein aggregates (associated with TSEs) and alpha-synuclein protein fibrils (associated with PD and Lewy Body dementia).
- a “neurodegenerative protein” is the form of the protein which accumulates during the neurodegenerative disorder, typically a mutant or mis-folded form.
- AGE AGE-modified protein or peptide
- glycation end-product refers to modified proteins or peptides that are formed as the result of the reaction of sugars with protein side chains that further rearrange and form irreversible cross-links. This process begins with a reversible reaction between a reducing sugar and an amino group to form a Schiff base, which proceeds to form a covalently-bonded Amadori rearrangement product. Once formed, the Amadori product undergoes further rearrangement to produce AGEs.
- AGE-modified proteins and antibodies to AGE-modified proteins are described in U.S. Pat. No.
- AGEs may be identified by the presence of AGE modifications (also referred to as AGE epitopes or AGE moieties) such as 2-(2-furoyI)-4(5)-(2-furanyl)-1H-imidazole (“FFI”); 5-hydroxymethyl-1-alkylpyrrole-2-carbaldehyde (“Pyrraline”); 1-alkyl-2-formyl-3,4-diglycosyl pyrrole (“AFGP”), a non-fluorescent model AGE; carboxymethyllysine; and pentosidine.
- AGE modifications also referred to as AGE epitopes or AGE moieties
- FFI 2-(2-furoyI)-4(5)-(2-furanyl)-1H-imidazole
- Pyrraline 5-hydroxymethyl-1-alkylpyrrole-2-carbaldehyde
- AFGP 1-alkyl-2-formyl-3,4-diglycosyl pyrrole
- ALI another AGE, is described
- AGE antigen means a substance that elicits an immune response against an AGE-modified protein or peptide of a cell.
- the immune response against an AGE-modified protein or peptide of a cell does not include the production of antibodies to the non-AGE-modified protein or peptide.
- AGE antibody means an antibody specific for an AGE-modified protein or peptide of a cell.
- senescent cell means a cell which is in a state of irreversible proliferative arrest and expresses one or more biomarkers of senescence, such as activation of p16 ink4a or expression of ⁇ -galactosidase. Also included are cells which express one or more biomarkers of senescence, do not proliferate in vivo, but may proliferate in vitro under certain conditions, such as some satellite cells found in the muscles of ALS patients.
- increasing health span means reducing age-related phenotypes.
- Age-related phenotypes include, for example, sarcopenia, cataracts, loss of adipose tissue and lordokyphosis.
- the identification of a link between cellular senescence and sarcopenia allows for new treatment possibilities.
- the immunogenic agent of a vaccine is an AGE-modified protein or peptide
- the immune system of an immunized subject may kill or induce apoptosis in cells expressing the AGE-modified protein or peptide.
- the present invention uses enhanced clearance of cells expressing AGE-modified proteins or peptides (AGE-modified cells) to treat or ameliorate sarcopenia.
- Vaccination against AGE-modified proteins or peptides of a cell produces the desired result of controlling the presence of AGE-modified cells in a subject in need thereof.
- the continuous and virtually ubiquitous surveillance exercised by the immune system in the body in response to a vaccination allows maintaining low levels of AGE-modified cells in the body.
- Vaccination against AGE-modified proteins or peptides of a cell can help remove or kill senescent cells.
- the process of senescent cell removal or destruction allows vaccination against AGE-modified proteins or peptides of a cell to be used to treat sarcopenia.
- Vaccination against AGE-modified proteins or peptides of a cell may also be used for increasing health span. Health span may be increased by reducing age-related phenotypes.
- the vaccine may be used, for example, to prevent or delay the onset of cataracts, lordokyphosis or loss of adipose tissue.
- diseases or disorders that are associated with cellular senescence may also be treated or ameliorated by vaccination against AGE-modified proteins or peptides of a cell.
- the vaccine may be used to treat neurodegenerative disorders, cancer, cancer metastases or atherosclerosis.
- Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients.
- AGE antigens include AGE-modified proteins or peptides such as AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-I and II, AGE-hemoglobin, AGE-Na + /K + -ATPase, AGE-plasminogen, AGE-
- AGE-modified cells such as AGE-modified erythrocytes, whole, lysed, or partially digested, may also be used as AGE antigens.
- Suitable AGE antigens also include proteins or peptides that exhibit AGE modifications (also referred to as AGE epitopes or AGE moieties) such as carboxymethyllysine, carboxyethyllysine, pentosidine, pyrraline, FFI, AFGP and ALI. Further details of some of these AGE-modified proteins or peptides and their preparation are described in Bucala.
- a particularly preferred AGE antigen is a protein or peptide that exhibits a carboxymethyllysine AGE modification.
- Carboxymethyllysine also known as CML, N(epsilon)-(carboxymethyl)lysine, N(6)-carboxymethyllysine, or 2-Amino-6-(carboxymethylamino)hexanoic acid
- CML-modified proteins or peptides are recognized by the receptor RAGE which is expressed on a variety of cells.
- CML has been well-studied and CML-related products are commercially available. For example, Cell Biolabs, Inc. sells CML-BSA antigens, CML polyclonal antibodies, CML immunoblot kits, and CML competitive ELISA kits (www.cellbiolabs.com/cml-assays).
- AGE antigens may be conjugated to carrier proteins to enhance antibody production in a subject.
- Antigens that are not sufficiently immunogenic alone may require a suitable carrier protein to stimulate a response from the immune system.
- suitable carrier proteins include keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, cholera toxin, labile enterotoxin, silica particles and soybean trypsin inhibitor.
- KLH keyhole limpet hemocyanin
- serum albumin serum albumin
- bovine thyroglobulin cholera toxin
- labile enterotoxin silica particles
- soybean trypsin inhibitor e.g., the carrier protein is KLH.
- KLH has been extensively studied and has been identified as an effective carrier protein in experimental cancer vaccines.
- a preferred AGE antigen-carrier protein conjugate is CML-KLH.
- Adjuvants include mineral compounds such as aluminum salts, oil emulsions, bacterial products, liposomes, immunostimulating complexes and squalene.
- Aluminum compounds are the most widely used adjuvants in human and veterinary vaccines. These aluminum compounds include aluminum salts such as aluminum phosphate (AIPO 4 ) and aluminum hydroxide (Al(OH) 3 ) compounds, typically in the form of gels, and are generically referred to in the field of vaccine immunological adjuvants as “alum.”
- Aluminum hydroxide is a poorly crystalline aluminum oxyhydroxide having the structure of the mineral boehmite.
- Aluminum phosphate is an amorphous aluminum hydroxyphosphate.
- Negatively charged species can absorb onto aluminum hydroxide gels at neutral pH
- positively charged species can absorb onto aluminum phosphate gels at neutral pH. It is believed that these aluminum compounds provide a depot of antigen at the site of administration, thereby providing a gradual and continuous release of antigen to stimulate antibody production. Aluminum compounds tend to more effectively stimulate a cellular response mediated by Th2, rather than Th1 cells.
- Emulsion adjuvants include water-in-oil emulsions (for example, Freund's adjuvants, such as killed mycobacteria in oil emulsion) and oil-in-water emulsions (for example, MF-59).
- Emulsion adjuvants include an immunogenic component, for example squalene (MF-59) or mannide oleate (Incomplete Freund's Adjuvants), which can induce an elevated humoral response, increased T cell proliferation, cytotoxic lymphocytes and cell-mediated immunity.
- Liposomal or vesicular adjuvants have lipophilic bilayer domains and an aqueous milieu which can be used to encapsulate and transport a variety of materials, for example an antigen.
- Paucilamellar vesicles can be prepared by mixing, under high pressure or shear conditions, a lipid phase comprising a non-phospholipid material (for example, an amphiphile surfactant; see U.S. Pat. Nos.
- a sterol optionally a sterol, and any water-immiscible oily material to be encapsulated in the vesicles (for example, an oil such as squalene oil and an oil-soluble or oil-suspended antigen); and an aqueous phase such as water, saline, buffer or any other aqueous solution used to hydrate the lipids.
- a sterol optionally a sterol, and any water-immiscible oily material to be encapsulated in the vesicles
- an oil such as squalene oil and an oil-soluble or oil-suspended antigen
- an aqueous phase such as water, saline, buffer or any other aqueous solution used to hydrate the lipids.
- Liposomal or vesicular adjuvants are believed to promote contact of the antigen with immune cells, for example by fusion of the vesicle to the immune cell membrane, and preferentially stimulate
- adjuvants include Mycobacterium bovis bacillus Calmette-Guérin (BCG), quill-saponin and unmethylated CpG dinucleotides (CpG motifs). Additional adjuvants are described in U.S. Patent Application Publication Pub. No. US 2010/0226932 (Sep. 9, 2010) and Jiang, Z-H. etal. “Synthetic vaccines: the role of adjuvants in immune targeting”, Current Medicinal Chemistry , Vol. 10(15), pp. 1423-39 (2003). Preferable adjuvants include Freund's complete adjuvant and Freund's incomplete adjuvant.
- the vaccine may optionally include one or more preservatives, such as antioxidants, antibacterial and antimicrobial agents, as well as combinations thereof.
- preservatives such as antioxidants, antibacterial and antimicrobial agents, as well as combinations thereof.
- examples include benzethonium chloride, ethylenediamine-tetraacetic acid sodium (EDTA), thimerosal, phenol, 2-phenoxyethanol, formaldehyde and formalin; antibacterial agents such as amphotericin B, chlortetracycline, gentamicin, neomycin, polymyxin B and streptomycin; antimicrobial surfactants such as polyoxyethylene-9, 10-nonyl phenol (Triton N-101, octoxynol-9), sodium deoxycholate and polyoxyethylated octyl phenol (Triton X-l00).
- the production and packaging of the vaccine may eliminate the need for a preservative. For example, a vaccine that has been sterilized
- vaccines include pharmaceutically acceptable excipients, such as stabilizers, thickening agents, toxin detoxifiers, diluents, pH adjusters, tonicity adjustors, surfactants, antifoaming agents, protein stabilizers, dyes and solvents.
- pharmaceutically acceptable excipients such as stabilizers, thickening agents, toxin detoxifiers, diluents, pH adjusters, tonicity adjustors, surfactants, antifoaming agents, protein stabilizers, dyes and solvents.
- excipients examples include hydrochloric acid, phosphate buffers, sodium acetate, sodium bicarbonate, sodium borate, sodium citrate, sodium hydroxide, potassium chloride, potassium chloride, sodium chloride, polydimethylsilozone, brilliant green, phenol red (phenolsulfon-phthalein), glycine, glycerin, sorbitol, histidine, monosodium glutamate, potassium glutamate, sucrose, urea, lactose, gelatin, sorbitol, polysorbate 20, polysorbate 80 and glutaraldehyde.
- hydrochloric acid phosphate buffers, sodium acetate, sodium bicarbonate, sodium borate, sodium citrate, sodium hydroxide, potassium chloride, potassium chloride, sodium chloride, polydimethylsilozone, brilliant green, phenol red (phenolsulfon-phthalein), glycine, glycerin, sorbitol, histidine, monosodium glutamate, potassium glut
- the vaccine may be provided in unit dosage form or in multidosage form, such as 2-100 or 2-10 doses.
- the unit dosages may be provided in a vial with a septum, or in a syringe with or without a needle.
- the vaccine may be administered intravenously, subdermally or intraperitoneally.
- the vaccine is sterile.
- the vaccine may be administered one or more times, such as 1 to 10 times, including 2, 3, 4, 5, 6, 7, 8 or 9 times, and may be administered over a period of time ranging from 1 week to 1 year, 2-10 weeks or 2-10 months. Furthermore, booster vaccinations may be desirable, over the course of 1 year to 20 years, including 2, 5, 10 and 15 years.
- a subject that receives a vaccine for AGE-modified proteins or peptides of a cell may be tested to determine if he or she has developed an immunity to the AGE-modified proteins or peptides. Suitable tests may include blood tests for detecting the presence of an antibody, such as immunoassays or antibody titers.
- an immunity to AGE-modified proteins or peptides may be determined by measuring changes in muscle mass over time. For example, a baseline muscle mass in a subject may be measured followed by administration of the vaccine for AGE-modified proteins or peptides of a cell. Immunity to AGE-modified proteins or peptides may be determined by periodically measuring muscle mass in the subject and comparing the subsequent measurements to the baseline measurement.
- a subject may be considered to have developed an immunity to AGE-modified proteins or peptides if he or she does not demonstrate loss of muscle mass between subsequent measurements or over time.
- concentration and/or number of senescent cells in fat or muscle tissue may also be monitored. Vaccination and subsequent testing may be repeated until the desired therapeutic result is achieved.
- the vaccination process may be designed to provide immunity against multiple antibodies
- a single AGE antigen may induce the production of AGE antibodies which are capable of binding to multiple AGE moieties.
- the vaccine may contain multiple AGE antigens.
- a subject may receive multiple vaccines, where each vaccine contains a different AGE antigen.
- Any mammal that could develop sarcopenia or other diseases or disorders associated with cellular senescence may be treated by the methods herein described.
- Humans are a preferred mammal for treatment.
- Other mammals that may be treated include mice, rats, goats, sheep, cows, horses and companion animals, such as dogs or cats.
- a subject in need of treatment may be identified by the diagnosis of a disease or disorder that is known to cause elevated levels of AGEs such as, for example, diabetes (both Type 1 and Type 2), or the presence of a pathological condition associated with AGEs such as, for example, atherosclerosis, inflammation, retinopathy, nephropathy, stroke, endothelial cell dysfunction, neurodegenerative disorders or cancer.
- subjects may be identified for treatment based on their age.
- a human over 75 years of age may be treated for sarcopenia, while a human under 30 years of age might not be identified as in need of treatment for sarcopenia.
- any of the mammals or subjects identified above may be excluded from the patient population in need of treatment for sarcopenia.
- a human subject may be identified as having sarcopenia or in need of treatment if (1) the subject is at least 25 years old and (2) his or her measured muscle mass and measured muscle function are two standard deviations or more below the mean value for healthy 25 year olds of the same gender and no alternative pathology has been identified to account for the reduced muscle mass and reduced muscle function.
- a subject being treated for sarcopenia is at least 40 years old. More preferably, a subject being treated for sarcopenia is at least 50 years old. Most preferably, a subject being treated for sarcopenia is at least 60 years old.
- a subject may be identified as having sarcopenia or in need of treatment if (1) his or her gait speed is less than 1.0 m/s across a 4 m course and (2) he or she has an objectively measured low muscle mass, such as, for example, an appendicular mass relative to the square of height less than or equal to 7.23 kg/m 2 for male subjects or less than or equal to 5.67 kg/m 2 for female subjects.
- an objectively measured low muscle mass such as, for example, an appendicular mass relative to the square of height less than or equal to 7.23 kg/m 2 for male subjects or less than or equal to 5.67 kg/m 2 for female subjects.
- Any mammal that could develop neurodegenerative disorders may be treated by the methods herein described.
- Humans are a preferred mammal for treatment.
- Other mammals that may be treated include mice, rats, goats, sheep, cows, horses and companion animals, such as dogs or cats.
- a subject in need of treatment may be identified by the diagnosis of a neurodegenerative disorder.
- a mammal that could develop metastatic cancer may be treated by the methods herein described.
- Humans are a preferred mammal for treatment.
- Other mammals that may be treated include mice, rats, goats, sheep, cows, horses and companion animals, such as dogs or cats.
- a subject in need of treatment may be identified by the diagnosis of a cancer.
- Cancers which are particularly subject to metastasis include lung cancer, melanoma, colon cancer, renal cell carcinoma, prostate cancer, cancer of the cervix, bladder cancer, rectal cancer, esophageal cancer, liver cancer, mouth and throat cancer, multiple myeloma, ovarian cancer, and stomach cancer. Treatment may be of patients experiencing metastatic cancer.
- Treatment may also be administered to patients who have cancer, but prior to any identified metastasis, in order to prevent metastasis.
- a subject that receives administration of an anti-AGE antibody may be tested to determine if it has been effective to treat the cancer by examining the patient for the spread of the cancer to different parts of the body, particularly in lymph nodes. Administration of antibody and subsequent testing may be repeated until the desired therapeutic result is achieved.
- Example 1 An AGE-RNAse containing vaccine in a human subject.
- AGE-RNAse is prepared by incubating RNAse in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-RNAse solution is dialyzed and the protein content is measured. Aluminum hydroxide or aluminum phosphate, as an adjuvant, is added to 100 pg of the AGE-RNAse. Formaldehyde or formalin is added as a preservative to the preparation. Ascorbic acid is added as an antioxidant.
- the vaccine also includes phosphate buffer to adjust the pH and glycine as a protein stabilizer.
- the composition is injected into a human subject subcutaneously.
- the subject's muscle mass is measured at'the time of injection to establish a baseline muscle mass value.
- the patient's muscle mass is measured again after one month.
- the one-month muscle mass value is compared to the baseline value. Additional injections are performed and additional muscle mass measurements are taken every month until the muscle mass measurement indicates no change, or an increase, from the baseline value.
- Example 2 Injection regimen for an AGE-RNAse containing vaccine in a human subject.
- Example 2 The same vaccine as described in Example 1 is injected into a human subject.
- the titer of antibodies to AGE-RNAse is determined by ELISA after two weeks. Additional injections are performed after three weeks and six weeks, respectively. Further titer determination is performed two weeks after each injection.
- Example 3 An AGE-hemoglobin containing vaccine in a human subject.
- AGE-hemoglobin is prepared by incubating human hemoglobin in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-hemoglobin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 1, except AGE-hemoglobin is substituted for AGE-RNAse.
- Example 1 The number of senescent cells in the subject's adipose tissue is measured at the time of injection to establish a baseline number of senescent cells.
- the number of senescent cells in the subject's adipose tissue is measured again two months after injection and is compared to the baseline number of senescent cells. Additional injections are performed and additional senescent cell measurements are taken every two months to determine if the number of senescent cells in adipose tissue is increasing or decreasing, or if there is no change in the number of senescent cells in adipose tissue.
- Example 4 An AGE-human serum albumin containing vaccine in a human subject.
- AGE-human serum albumin is prepared by incubating human serum albumin in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-human serum albumin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 1, except AGE-human serum albumin is substituted for AGE-RNAse. Administration is carried out as in Example 1, or as in Example 2.
- Example 5 In vivo study of the administration of anti-AGE antibody.
- the antibody was administered to the aged CD1(lCR) mouse (Charles River Laboratories), twice daily by intravenous injection, once a week, for three weeks (Days 1, 8 and 15), followed by a 10 week treatment-free period.
- the test antibody was a commercially available mouse anti-AGE antibody raised against carboxymethyl lysine conjugated with keyhole limpet hemocyanin. A control reference of physiological saline was used in the control animals.
- mice referred to as “young” were 8 weeks old, while mice referred to as “old” were 88 weeks ( ⁇ 2 days) old. No adverse events were noted from the administration of the antibody.
- the different groups of animals used in the study are shown in Table 1.
- p16 INK4A mRNA a marker for senescent cells, was quantified in adipose tissue of the groups by Real Time-qPCR. The results are shown in Table 2.
- the mass of the gastrocnemius muscle was also measured, to determine the effect of antibody administration on a classic sign of aging, sarcopenia.
- the results are shown in Table 3. The results indicate that administration of the antibody increased muscle mass as compared to controls, but only at the higher dosage of 5.0 ⁇ g/gm/BID/week.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Various diseases and disorders associated with cellular senescence may be treated by immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell. Immunizing a subject includes administering a vaccine that comprises an AGE antigen. Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients.
Description
- Sarcopenia is the loss of muscle mass, quality and strength associated with aging. Humans begin to lose muscle mass and function at some point in the third decade of life. This loss of muscle mass typically accelerates around age 75. Sarcopenia develops in both physically active and physically inactive people. As the average human lifespan continues to increase, sarcopenia is becoming a significant health concern. The loss of muscle mass from sarcopenia may lead to poor balance, reduced gait speed and frailty. Individuals suffering from sarcopenia are more susceptible to injury and disability, and may be unable to live independently as a result. The spread of sarcopenia will likely result in increases in health care and assisted living expenses.
- Sarcopenia has been considered to be an inevitable result of aging and the natural deterioration of the body over time. The primary treatment for sarcopenia is exercise. Physical exercise, particularly resistance training or strength training, can reduce the impact of sarcopenia. Testosterone, anabolic steroids, ghrelin, vitamin D, angiotensin converting enzyme inhibitors (ACE inhibitors), eicosapentaenoic acid (EPA), myostatin, selective androgen receptor modulators (SARMs), urocortin II (Ucn2) and hormone replacement therapy have been investigated or are being studied as potential treatments for sarcopenia. Despite this research, there are currently no U.S. Food and Drug Administration (FDA)-approved agents for treating sarcopenia.
- A recent study has identified a causal link between cellular senescence and age-related disorders, such as sarcopenia. A research team at the Mayo Clinic in Rochester, Minn., demonstrated that effects of aging in mice could be delayed by eliminating senescent cells in their fat and muscle tissues without overt side effects (Baker, D. J. et al., “Clearance of p16ink4a-positive senescent cells delays ageing-associated disorders”, Nature, Vol. 479, pp. 232-236, (2011)). Elimination of senescent cells in transgenic mice was shown to substantially delay the onset of sarcopenia and cataracts, and to reduce senescence indicators in skeletal muscle and the eye. The study established that life-long and late-life treatment of transgenic mice for removal of senescent cells has no negative side effects and selectively delays age-related phenotypes that depend on cells (Id., page 234, col. 2, line 16 through page 235, col. 1, line 2). The authors theorized that removal of senescent cells may represent an avenue for treating or delaying age-related diseases in humans and improving healthy human lifespan (Id., page 235, col. 2, lines 38-51).
- Senescent cells are cells that are partially-functional or non-functional and are in a state of irreversible proliferative arrest. Senescence is a distinct state of a cell, and is associated with biomarkers, such as activation of the biomarker p16ink4a, and expression of β-galactosidase. Senescence begins with damage or stress (such as overstimulation by growth factors) of cells.
- Advanced glycation end-products (AGEs; also referred to AGE-modified proteins, or glycation end-products) arise from a non-enzymatic reaction of sugars with protein side-chains in aging cells (Ando, K. et al., Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products during Aging in the Circulation, Biochem Biophys Res Commun., Vol. 258, 123, 125 (1999)). This process begins with a reversible reaction between the reducing sugar and the amino group to form a Schiff base, which proceeds to form a covalently-bonded Amadori rearrangement product. Once formed, the Amadori product undergoes further rearrangement to produce AGEs. Hyperglycemia, caused by diabetes mellitus (DM), and oxidative stress promote this post-translational modification of membrane proteins (Lindsey JB, et al., “Receptor For Advanced Glycation End-Products (RAGE) and soluble RAGE (sRAGE): Cardiovascular Implications,” Diabetes Vascular Disease Research, Vol. 6(1), 7-14, (2009)). AGEs may also be formed from other processes. For example, the advanced glycation end product, Nε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. AGEs have been associated with several pathological conditions including diabetic complications, inflammation, retinopathy, nephropathy, atherosclerosis, stroke, endothelial cell dysfunction, and neurodegenerative disorders (Bierhaus A, “AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept,” Cardiovasc Res, Vol. 37(3), 586-600 (1998)).
- AGE-modified proteins are also a marker of senescent cells. This association between glycation end-product and senescence is well known in the art. See, for example, Gruber, L. (WO 2009/143411, 26 Nov. 2009), Ando, K. et al. (Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products during Aging in the Circulation, Biochem Biophys Res Commun., Vol. 258, 123, 125 (1999)), Ahmed, E.K. et al. (“Protein Modification and Replicative Senescence of WI-38 Human Embryonic Fibroblasts” Aging Cells, vol. 9, 252, 260 (2010)), Vlassara, H. et al. (Advanced Glycosylation Endproducts on Erythrocyte Cell Surface Induce Receptor-Mediated Phagocytosis by Macrophages, J. Exp. Med., Vol. 166, 539, 545 (1987)) and Vlassara et al. (“High-affinity-receptor-mediated Uptake and Degradation of Glucose-modified Proteins: A Potential Mechanism for the Removal of Senescent Macromolecules” Proc. Nat!. Acad. Sci. USAl , Vol. 82, 5588, 5591 (1985)). Furthermore, Ahmed, E.K. etal. indicates that glycation end-products are “one of the major causes of spontaneous damage to cellular and extracellular proteins” (Ahmed, E.K. et al., see above, page 353). Accordingly, the accumulation of glycation end-products is associated with senescence and lack of function.
- Cellular senescence and the accumulation of AGEs have been implicated in a number of diseases and disorders in addition to sarcopenia and age-related disorders. Senescence of cells in the central nervous system such as glial cells, astrocytes and microglial cells has been associated with neurodegenerative disorders. Abnormal accumulation of senescent astrocytes has been associated with Alzheimer's disease (AD) (Bhat, R. et al., “Astrocyte Senescence as a Component of Alzheimer's Disease”, PLOS ONE, Vol. 7(9), e45069, pp. 1-10 (September 2012)). Microglial cell senescence associated with normal aging is exacerbated by the presence of the amyloid plaques indicative of AD (Flanary, B. E. et al., “Evidence That Aging And Amyloid Promote Microglial Cell Senescence”, Rejuvenation Research, Vol. 10(1), pp. 61-74 (March 2007)). The presence of AGEs with astrocytes and microglial cells in AD is further evidence of the presence of senescent cells (Takeda, A., et aL “Advanced glycation end products co-localize with astrocytes and microglial cells in Alzheimer's disease brain”, Acta Neuropathologica, Vol. 95, pp. 555-558 (1998)). On the basis of recently reported findings, Chinta et aL proposed that environmental stressors associated with Parkinson's disease (PD) may act in part by eliciting senescence within non-neuronal glial cells, contributing to the characteristic decline in neuronal integrity that occurs in this disorder (Chinta, S. J. et al. “Environmental stress, ageing and glial cell senescence: a novel mechanistic link to Parkinson's disease?”, J Intern Med, Vol. 273, pp. 429-436 (2013)). Astrocyte senescence is also associated with PD (M. Mori, “The Parkinsonian Brain: Cellular Senescence and Neurodegeneration, SAGE (Jun. 30, 2015) (sage.buckinstitute.org/the-parkinsonian-brain-cellular-senescence-and-neurodegeneration/). In a rodent model of familial amyotrophic lateral sclerosis (ALS) overexpressing mutant superoxide dismutase-1 (m-SOD1), the rate of astrocytes acquiring a senescent phenotype is accelerated (Das, M. M. and Svendsen, C. N., “Astrocytes show reduced support of motor neurons with aging that is accelerated in a rodent model of ALS”, Neurobiology of Aging, Vol. 36, pp. 1130-1139 (2015)). Even in multiple sclerosis (MS), microglia and macrophages are shifted toward a strongly proinflammatory phenotype, reminiscent of SASP, and may potentiate neuronal damage by releasing proinflammatory cytokines and molecules (Luessi, F., et aL “Neurodegeneration in multiple sclerosis: novel treatment strategies” Expert Rev. Neurother., Vol 9, pp.1061-1077 (2012)).
- Some neurodegenerative disorders are associated with abnormal cellular senescence outside the central nervous system. Most satellite cells, also known as myosatellite cells, present in the muscle tissue of ALS patients exhibit an abnormal senescent-like morphology, although they may be capable of proliferating in vitro (Pradat, P.-F. et al., “Abnormalities of satellite cells function in amyotrophic lateral sclerosis” Amyotrophic Lateral Sclerosis, Vol. 12, pp. 264-271 (2011)). Satellite cells are small multipotent cells found in mature muscle, which are able to give rise to additional satellite cells, or differentiate into myoblasts as well as provide additional myonuclei. In an animal model of Duchenne muscular dystrophy (MD), reduced proliferative capacity and premature senescence of myoblasts was observed (Wright, W. E., “Myoblast Senescence in Muscular Dystrophy” Exp Cell Res, Vol. 157, pp. 343-354 (1985)). Myoblasts are precursor cells which differentiate into myocytes (also referred to as muscle cells).
- Neurodegenerative disorders are also associated with abnormal protein accumulations (King, O.D., et al., “The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease” Brain Res. Vol.1462, pp. 61-80 (2012)). A characteristic of PD and Lewy body dementia is the formation of Lewy bodies that form inside nerve cells. The primary structural component of the Lewy bodies is alpha-synuclein protein, in the form of fibrils. The presence of tangles and plaques are a characteristic of AD, the presence of which is used to definitively diagnose the condition. Plaques, composed of beta-amyloid protein (also referred to as amyloid beta, Aβ or Abeta), accumulate between nerve cells. Tangles, composed of tau protein, form twisted fibers within cells. Prion diseases (also known as transmissible spongiform encephalopathies (TSEs)), include a variety of human and animal disorder such as Creutzfeldt-Jakob disease, variant Creutzfeldt-Jakob disease, bovine spongiform encephalopathy (“mad cow” disease), scrapie (in sheep and goats), chronic wasting disease (in deer and elk), kuru and fatal familial insomnia. Prion protein is a misfolded protein molecule which may propagate by transmitting a misfolded protein state, resulting in the accumulation of the misfolded protein and causing tissue damage and cell death (Dobson, D. M., “The structural basis of protein folding and its links with human disease” Phil. Trans. R. Soc. Lond. B, Vol. 356, pp. 133-145 (2001)). In these diseases, it is believed the protein is a normal protein which misfolds or forms an abnormal aggregate. In the case of some patients with familial ALS, a mutated superoxide dismutase-1 (SOD1) forms inclusions and accumulates (Kato, S., etal. “Advanced glycation endproduct-modified superoxide dismutase-1 (SOD1)-positive inclusions are common to familial amyotrophic lateral sclerosis patients with SOD1 gene mutations and transgenic mice expressing human SOD1 with a G85R mutation” Acta Neuropathol, Vol. 100, pp. 490-505 (2000)).
- The damage or stress that causes cellular senescence also negatively impacts mitochondrial DNA in the cells to cause them to produce free radicals which react with sugars in the cell to form methyl glyoxal (MG). MG in turn reacts with proteins or lipids to generate advanced glycation end products. In the case of the protein component lysine, MG reacts to form carboxymethyllysine, which is an AGE.
- Damage or stress to mitochondrial DNA also sets off a DNA damage response which induces the cell to produce cell cycle blocking proteins. These blocking proteins prevent the cell from dividing. Continued damage or stress causes mTOR production, which in turn activates protein synthesis and inactivates protein breakdown. Further stimulation of the cells leads to programmed cell death (apoptosis). p16 is a protein involved in regulation of the cell cycle, by inhibiting the S phase. It can be activated during ageing or in response to various stresses, such as DNA damage, oxidative stress or exposure to drugs. p16 is typically considered a tumor suppressor protein, causing a cell to become senescent in response to DNA damage and irreversibly preventing the cell from entering a hyperproliferative state. However, there has been some ambiguity in this regard, as some tumors show overexpression of p16, while other show downregulated expression. Evidence suggests that overexpression of p16 is some tumors results from a defective retinoblastoma protein (“Rb”). p16 acts on Rb to inhibit the S phase, and Rb downregulates p16, creating negative feedback. Defective Rb fails to both inhibit the S phase and downregulate p16, thus resulting in overexpression of p16 in hyperproliferating cells. Romagosa, C. et al., p16ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors, Oncogene, Vol. 30, 2087-2097 (2011).
- Senescent cells are also known to fuel the growth of cancer cells. Senescent cells are associated with secretion of many factors involved in intercellular signaling, including pro-inflammatory factors; secretion of these factors has been termed the senescence-associated secretory phenotype, or SASP. One study showed that senescent mesenchymal stem cells promote proliferation and migration of breast cancer cells by the secretion of IL-6 (Di, G-h. et al. IL-6 Secreted from Senescent Mesenchymal Stem Cells Promotes Proliferation and migration of Breast Cancer Cells, PLOS One, Vol. 9, 11, e113572 (2014)). Another study showed that senescent human fibroblasts increase the growth of tumors by the secretion of matrix metalloproteinase (Liu, D. et al. Senescent Human Fibroblasts Increase the Early Growth of Xenograft Tumors via Matrix Metalloproteinase Secretion, Cancer Res, Vol. 67, 3117-3126 (2007)).
- Vaccines have been widely used since their introduction by Edward Jenner in the 1770s to confer immunity against a wide range of diseases and afflictions. Vaccine preparations contain a selected immunogenic agent capable of stimulating immunity to an antigen. Typically, antigens are used as the immunogenic agent in vaccines, such as, for example, viruses, either killed or attenuated, and purified viral components. Antigens used in the production of cancer vaccines include, for example, tumor-associated carbohydrate antigens (TACAs), dendritic cells, whole cells and viral vectors. Different techniques are employed to produce the desired amount and type of antigen being sought. For example, pathogenic viruses are grown either in eggs or cells. Recombinant DNA technology is often utilized to generate attenuated viruses for vaccines.
- Immunity is a long-term immune response, either cellular or humoral. A cellular immune response is activated when an antigen is presented, preferably with a co-stimulator to a T-cell which causes it to differentiate and produce cytokines. The cells involved in the generation of the cellular immune response are two classes of T-helper (Th) cells, Th1 and Th2. Th1 cells stimulate B cells to produce predominantly antibodies of the IgG2A isotype, which activates the complement cascade and binds the Fc receptors of macrophages, while Th2 cells stimulate B cells to produce IgG1 isotype antibodies in mice, IgG4 isotype antibodies in humans, and IgE isotype antibodies. The human body also contains “professional” antigen-presenting cells such as dendritic cells, macrophages, and B cells.
- A humoral immune response is triggered when a B cell selectively binds to an antigen and begins to proliferate, leading to the production of a clonal population of cells that produce antibodies that specifically recognize that antigen and which may differentiate into antibody-secreting cells, referred to as plasma-cells or memory-B cells. Antibodies are molecules produced by B-cells that bind a specific antigen. The antigen-antibody complex triggers several responses, either cell-mediated, for example by natural killers (NK) or macrophages, or serum-mediated, for example by activating the complement system, a complex of several serum proteins that act sequentially in a cascade that result in the lysis of the target cell.
- Immunological adjuvants (also referred to simply as “adjuvants”) are the component(s) of a vaccine which augment the immune response to the immunogenic agent. Adjuvants function by attracting macrophages to the immunogenic agent and then presenting the agent to the regional lymph nodes to initiate an effective antigenic response. Adjuvants may also act as carriers themselves for the immunogenic agent. Adjuvants may induce an inflammatory response, which may play an important role in initiating the immune response. Adjuvants include mineral compounds such as aluminum salts, oil emulsions, bacterial products, liposomes, immunostimulating complexes and squalene.
- Other components of vaccines include pharmaceutically acceptable excipients, preservatives, diluents and pH adjusters. A variety of these components of vaccines, as well as adjuvants, are described in www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf and Vogel, F. R. et aL, “A compendium of vaccine adjuvants and excipients”, Pharmaceutical Biotechnology, Vol. 6, pp. 141-228 (1995).
- Vaccines may therefore be used to stimulate the production of antibodies in the body and provide immunity against antigens. When an antigen is introduced to a subject that has been vaccinated and developed immunity to that antigen, the immune system may destroy or remove cells that express the antigen.
- In a first aspect, the invention is a method of treating or preventing a disease or disorder associated with cellular senescence comprising immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell.
- In a second aspect, the invention is a method of treating a subject with a disease or disorder associated with cellular senescence comprising administering a first vaccine comprising a first AGE antigen and administering a second vaccine comprising a second AGE antigen. The second AGE antigen is different from the first AGE antigen.
- In a third aspect, the invention is use of an AGE antigen for the manufacture of a medicament for treating or preventing a disease or disorder associated with cellular senescence.
- In a fourth aspect, the invention is a composition comprising an AGE antigen for use in treating or preventing a disease or disorder associated with cellular senescence.
- In a fifth aspect, the invention is a composition comprising an AGE antigen for use in treating sarcopenia.
- In a sixth aspect, the invention is a composition comprising an AGE antigen for use in promoting tissue or organ regeneration.
- In a seventh aspect, the invention is a composition comprising an AGE antigen for use in promoting regenerative processes or overcoming aging effects.
- In an eighth aspect, the invention is a composition comprising an AGE antigen for use in treating atherosclerosis.
- In an ninth aspect, the invention is a composition comprising an AGE antigen for use in preventing or delaying the onset of cataracts.
- In a tenth aspect, the invention is a composition comprising an AGE antigen for use in preventing or delaying the onset of loss of adipose tissue.
- In an eleventh aspect, the invention is a composition comprising an AGE antigen for use in preventing or delaying the onset of lordokyphosis.
- In a twelfth aspect, the invention is a composition comprising an AGE antigen for use in treating inflammation or auto-immune disorders.
- In a thirteenth aspect, the invention is a composition comprising an AGE antigen for use in treating neurodegenerative disorders.
- In a fourteenth aspect, the invention is a composition comprising an AGE antigen for use in treating cancer or cancer metastases.
- In a fifteenth aspect, the invention is a composition comprising an AGE antigen for use in increasing health span.
- In a sixteenth aspect, the invention is a method of reducing the number of AGE-modified cells in a patient, comprising administering a vaccine comprising an AGE antigen.
- The term “peptide” means a molecule composed of 2-50 amino acids.
- The term “protein” means a molecule composed of more than 50 amino acids.
- The term “sarcopenia” means the syndrome characterized by the presence of (1) low muscle mass and (2) low muscle function (low muscle strength or reduced physical performance). Muscle mass may be measured by body imaging techniques, such as computed tomography scanning (CT scan), magnetic resonance imaging (MRI) or dual energy X-ray absorptiometry (DXA or DEXA); bioimpedance analysis (BIA); body potassium measurement, such as total body potassium (TBK) or partial body potassium (PBK); or anthropometric measurements, such as mid-upper arm circumference, skin fold thickness or calf circumference. Preferably, muscle mass is measured by CT scan, MRI or DXA. Muscle strength may be measured by handgrip strength, knee flexion/extension or peak expiratory flow. Preferably, muscle strength is measured by handgrip strength. Physical performance may be measured by the Short Physical Performance Battery, gait speed measurement, timed get-up-and-go (TGUG) or the stair climb power test. Preferably, physical performance is measured by gait speed measurement. A subject may be identified as having sarcopenia or in need of treatment if (1) the subject is at least 25 years old and (2) his or her measured muscle mass and measured muscle function are two standard deviations or more below the mean value for healthy 25 year olds of the same gender and no alternative pathology has been identified to account for the reduced muscle mass and reduced muscle function. Preferably, a subject being treated for sarcopenia is at least 40 years old. More preferably, a subject being treated for sarcopenia is at least 50 years old. Most preferably, a subject being treated for sarcopenia is at least 60 years old. Alternatively, a subject may be identified as having sarcopenia or in need of treatment if (1) his or her gait speed is less than 1.0 m/s across a 4 m course and (2) he or she has an objectively measured low muscle mass, such as, for example, an appendicular mass relative to the square of height less than or equal to 7.23 kg/m2 for male subjects or less than or equal to 5.67 kg/m2 for female subjects (Fielding, R. A., et al., “Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences”, Journal of the American Medical Directors Association, Vol. 12(4), pp. 249-256 (May 2011).
- The term “neurodegenerative disorder” means disorders which result in neurons loosing function and/or dying, in the central nervous system including the brain. Such disorders included central nervous system neurodegenerative disorders such as AD, PD, Lewy body dementia, MS, prion diseases (also known as transmissible spongiform encephalopathies (TSEs), including Creutzfeldt-Jakob disease, variant Creutzfeldt-Jakob disease, bovine spongiform encephalopathy (“mad cow” disease), scrapie (in sheep and goats), chronic wasting disease (in deer and elk), kuru and fatal familial insomnia), and ALS.
- “Neurodegenerative proteins” are proteins which accumulate in a patient having a neurodegenerative disorders and which are associated with the neurodegenerative disorder. Examples include, beta-amyloid protein plaques (associated with AD), tau protein tangles (associated with AD), mutated superoxide dismutase-1 (associated with ALS), prion protein aggregates (associated with TSEs) and alpha-synuclein protein fibrils (associated with PD and Lewy Body dementia). A “neurodegenerative protein” is the form of the protein which accumulates during the neurodegenerative disorder, typically a mutant or mis-folded form.
- The terms “advanced glycation end-product,” “AGE,” “AGE-modified protein or peptide,” and “glycation end-product” refer to modified proteins or peptides that are formed as the result of the reaction of sugars with protein side chains that further rearrange and form irreversible cross-links. This process begins with a reversible reaction between a reducing sugar and an amino group to form a Schiff base, which proceeds to form a covalently-bonded Amadori rearrangement product. Once formed, the Amadori product undergoes further rearrangement to produce AGEs. AGE-modified proteins and antibodies to AGE-modified proteins are described in U.S. Pat. No. 5,702,704 to Bucala (“Bucala”) and U.S. Pat. No. 6,380,165 to Al-Abed et al. (“Al-Abed”). Glycated proteins or peptides that have not undergone the necessary rearrangement to form AGEs, such as N-deoxyfructosyllysine found on glycated albumin, are not AGEs. AGEs may be identified by the presence of AGE modifications (also referred to as AGE epitopes or AGE moieties) such as 2-(2-furoyI)-4(5)-(2-furanyl)-1H-imidazole (“FFI”); 5-hydroxymethyl-1-alkylpyrrole-2-carbaldehyde (“Pyrraline”); 1-alkyl-2-formyl-3,4-diglycosyl pyrrole (“AFGP”), a non-fluorescent model AGE; carboxymethyllysine; and pentosidine. ALI, another AGE, is described in Al-Abed.
- The term “AGE antigen” means a substance that elicits an immune response against an AGE-modified protein or peptide of a cell. The immune response against an AGE-modified protein or peptide of a cell does not include the production of antibodies to the non-AGE-modified protein or peptide.
- The term “AGE antibody” means an antibody specific for an AGE-modified protein or peptide of a cell.
- The term “senescent cell” means a cell which is in a state of irreversible proliferative arrest and expresses one or more biomarkers of senescence, such as activation of p16ink4a or expression of β-galactosidase. Also included are cells which express one or more biomarkers of senescence, do not proliferate in vivo, but may proliferate in vitro under certain conditions, such as some satellite cells found in the muscles of ALS patients.
- The term “increasing health span” means reducing age-related phenotypes.
- Age-related phenotypes include, for example, sarcopenia, cataracts, loss of adipose tissue and lordokyphosis.
- The identification of a link between cellular senescence and sarcopenia allows for new treatment possibilities. For example, if the immunogenic agent of a vaccine is an AGE-modified protein or peptide, the immune system of an immunized subject may kill or induce apoptosis in cells expressing the AGE-modified protein or peptide.
- The present invention uses enhanced clearance of cells expressing AGE-modified proteins or peptides (AGE-modified cells) to treat or ameliorate sarcopenia. Vaccination against AGE-modified proteins or peptides of a cell produces the desired result of controlling the presence of AGE-modified cells in a subject in need thereof. The continuous and virtually ubiquitous surveillance exercised by the immune system in the body in response to a vaccination allows maintaining low levels of AGE-modified cells in the body. Vaccination against AGE-modified proteins or peptides of a cell can help remove or kill senescent cells. The process of senescent cell removal or destruction allows vaccination against AGE-modified proteins or peptides of a cell to be used to treat sarcopenia.
- Vaccination against AGE-modified proteins or peptides of a cell may also be used for increasing health span. Health span may be increased by reducing age-related phenotypes. The vaccine may be used, for example, to prevent or delay the onset of cataracts, lordokyphosis or loss of adipose tissue.
- Other diseases or disorders that are associated with cellular senescence may also be treated or ameliorated by vaccination against AGE-modified proteins or peptides of a cell. For example, the vaccine may be used to treat neurodegenerative disorders, cancer, cancer metastases or atherosclerosis.
- Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients. Examples of AGE antigens include AGE-modified proteins or peptides such as AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-I and II, AGE-hemoglobin, AGE-Na+/K+-ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-β-N-acetyl hexominase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE-132-microglobulin, AGE-sorbitol dehydrogenase, AGE-α1-antitrypsin, AGE-carbonate dehydratase, AGE-RNAse, AGE-low density lipoprotein, AGE-hexokinase, AGE-apo C-I, AGE-RNAse, AGE-hemoglobin such as AGE-human hemoglobin, AGE-albumin such as AGE-bovine serum albumin (AGE-BSA) and AGE-human serum albumin, AGE-low density lipoprotein (AGE-LDL) and AGE-collagen IV. AGE-modified cells, such as AGE-modified erythrocytes, whole, lysed, or partially digested, may also be used as AGE antigens. Suitable AGE antigens also include proteins or peptides that exhibit AGE modifications (also referred to as AGE epitopes or AGE moieties) such as carboxymethyllysine, carboxyethyllysine, pentosidine, pyrraline, FFI, AFGP and ALI. Further details of some of these AGE-modified proteins or peptides and their preparation are described in Bucala.
- A particularly preferred AGE antigen is a protein or peptide that exhibits a carboxymethyllysine AGE modification. Carboxymethyllysine (also known as CML, N(epsilon)-(carboxymethyl)lysine, N(6)-carboxymethyllysine, or 2-Amino-6-(carboxymethylamino)hexanoic acid) is found on proteins or peptides and lipids as a result of oxidative stress and chemical glycation, and has been correlated with aging. CML-modified proteins or peptides are recognized by the receptor RAGE which is expressed on a variety of cells. CML has been well-studied and CML-related products are commercially available. For example, Cell Biolabs, Inc. sells CML-BSA antigens, CML polyclonal antibodies, CML immunoblot kits, and CML competitive ELISA kits (www.cellbiolabs.com/cml-assays).
- AGE antigens may be conjugated to carrier proteins to enhance antibody production in a subject. Antigens that are not sufficiently immunogenic alone may require a suitable carrier protein to stimulate a response from the immune system. Examples of suitable carrier proteins include keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, cholera toxin, labile enterotoxin, silica particles and soybean trypsin inhibitor. Preferably, the carrier protein is KLH. KLH has been extensively studied and has been identified as an effective carrier protein in experimental cancer vaccines. A preferred AGE antigen-carrier protein conjugate is CML-KLH.
- Adjuvants include mineral compounds such as aluminum salts, oil emulsions, bacterial products, liposomes, immunostimulating complexes and squalene. Aluminum compounds are the most widely used adjuvants in human and veterinary vaccines. These aluminum compounds include aluminum salts such as aluminum phosphate (AIPO4) and aluminum hydroxide (Al(OH)3) compounds, typically in the form of gels, and are generically referred to in the field of vaccine immunological adjuvants as “alum.” Aluminum hydroxide is a poorly crystalline aluminum oxyhydroxide having the structure of the mineral boehmite. Aluminum phosphate is an amorphous aluminum hydroxyphosphate. Negatively charged species (for example, negatively charged antigens) can absorb onto aluminum hydroxide gels at neutral pH, whereas positively charged species (for example, positively charged antigens) can absorb onto aluminum phosphate gels at neutral pH. It is believed that these aluminum compounds provide a depot of antigen at the site of administration, thereby providing a gradual and continuous release of antigen to stimulate antibody production. Aluminum compounds tend to more effectively stimulate a cellular response mediated by Th2, rather than Th1 cells.
- Emulsion adjuvants include water-in-oil emulsions (for example, Freund's adjuvants, such as killed mycobacteria in oil emulsion) and oil-in-water emulsions (for example, MF-59). Emulsion adjuvants include an immunogenic component, for example squalene (MF-59) or mannide oleate (Incomplete Freund's Adjuvants), which can induce an elevated humoral response, increased T cell proliferation, cytotoxic lymphocytes and cell-mediated immunity.
- Liposomal or vesicular adjuvants (including paucilamellar lipid vesicles) have lipophilic bilayer domains and an aqueous milieu which can be used to encapsulate and transport a variety of materials, for example an antigen. Paucilamellar vesicles (for example, those described in U.S. Pat. No. 6,387,373) can be prepared by mixing, under high pressure or shear conditions, a lipid phase comprising a non-phospholipid material (for example, an amphiphile surfactant; see U.S. Pat. Nos. 4,217,344; 4,917,951; and 4,911,928), optionally a sterol, and any water-immiscible oily material to be encapsulated in the vesicles (for example, an oil such as squalene oil and an oil-soluble or oil-suspended antigen); and an aqueous phase such as water, saline, buffer or any other aqueous solution used to hydrate the lipids. Liposomal or vesicular adjuvants are believed to promote contact of the antigen with immune cells, for example by fusion of the vesicle to the immune cell membrane, and preferentially stimulate the Th1 sub-population of T-helper cells.
- Other types of adjuvants include Mycobacterium bovis bacillus Calmette-Guérin (BCG), quill-saponin and unmethylated CpG dinucleotides (CpG motifs). Additional adjuvants are described in U.S. Patent Application Publication Pub. No. US 2010/0226932 (Sep. 9, 2010) and Jiang, Z-H. etal. “Synthetic vaccines: the role of adjuvants in immune targeting”, Current Medicinal Chemistry, Vol. 10(15), pp. 1423-39 (2003). Preferable adjuvants include Freund's complete adjuvant and Freund's incomplete adjuvant.
- The vaccine may optionally include one or more preservatives, such as antioxidants, antibacterial and antimicrobial agents, as well as combinations thereof. Examples include benzethonium chloride, ethylenediamine-tetraacetic acid sodium (EDTA), thimerosal, phenol, 2-phenoxyethanol, formaldehyde and formalin; antibacterial agents such as amphotericin B, chlortetracycline, gentamicin, neomycin, polymyxin B and streptomycin; antimicrobial surfactants such as polyoxyethylene-9, 10-nonyl phenol (Triton N-101, octoxynol-9), sodium deoxycholate and polyoxyethylated octyl phenol (Triton X-l00). The production and packaging of the vaccine may eliminate the need for a preservative. For example, a vaccine that has been sterilized and stored in a sealed container may not require a preservative.
- Other components of vaccines include pharmaceutically acceptable excipients, such as stabilizers, thickening agents, toxin detoxifiers, diluents, pH adjusters, tonicity adjustors, surfactants, antifoaming agents, protein stabilizers, dyes and solvents. Examples of such excipients include hydrochloric acid, phosphate buffers, sodium acetate, sodium bicarbonate, sodium borate, sodium citrate, sodium hydroxide, potassium chloride, potassium chloride, sodium chloride, polydimethylsilozone, brilliant green, phenol red (phenolsulfon-phthalein), glycine, glycerin, sorbitol, histidine, monosodium glutamate, potassium glutamate, sucrose, urea, lactose, gelatin, sorbitol, polysorbate 20, polysorbate 80 and glutaraldehyde.
- The vaccine may be provided in unit dosage form or in multidosage form, such as 2-100 or 2-10 doses. The unit dosages may be provided in a vial with a septum, or in a syringe with or without a needle. The vaccine may be administered intravenously, subdermally or intraperitoneally. Preferably, the vaccine is sterile.
- [60] The vaccine may be administered one or more times, such as 1 to 10 times, including 2, 3, 4, 5, 6, 7, 8 or 9 times, and may be administered over a period of time ranging from 1 week to 1 year, 2-10 weeks or 2-10 months. Furthermore, booster vaccinations may be desirable, over the course of 1 year to 20 years, including 2, 5, 10 and 15 years.
- A subject that receives a vaccine for AGE-modified proteins or peptides of a cell may be tested to determine if he or she has developed an immunity to the AGE-modified proteins or peptides. Suitable tests may include blood tests for detecting the presence of an antibody, such as immunoassays or antibody titers. Alternatively, an immunity to AGE-modified proteins or peptides may be determined by measuring changes in muscle mass over time. For example, a baseline muscle mass in a subject may be measured followed by administration of the vaccine for AGE-modified proteins or peptides of a cell. Immunity to AGE-modified proteins or peptides may be determined by periodically measuring muscle mass in the subject and comparing the subsequent measurements to the baseline measurement. A subject may be considered to have developed an immunity to AGE-modified proteins or peptides if he or she does not demonstrate loss of muscle mass between subsequent measurements or over time. Alternatively, the concentration and/or number of senescent cells in fat or muscle tissue may also be monitored. Vaccination and subsequent testing may be repeated until the desired therapeutic result is achieved.
- The vaccination process may be designed to provide immunity against multiple
- AGE moieties. A single AGE antigen may induce the production of AGE antibodies which are capable of binding to multiple AGE moieties. Alternatively, the vaccine may contain multiple AGE antigens. In addition, a subject may receive multiple vaccines, where each vaccine contains a different AGE antigen.
- Any mammal that could develop sarcopenia or other diseases or disorders associated with cellular senescence may be treated by the methods herein described. Humans are a preferred mammal for treatment. Other mammals that may be treated include mice, rats, goats, sheep, cows, horses and companion animals, such as dogs or cats. A subject in need of treatment may be identified by the diagnosis of a disease or disorder that is known to cause elevated levels of AGEs such as, for example, diabetes (both Type 1 and Type 2), or the presence of a pathological condition associated with AGEs such as, for example, atherosclerosis, inflammation, retinopathy, nephropathy, stroke, endothelial cell dysfunction, neurodegenerative disorders or cancer. In addition, subjects may be identified for treatment based on their age. For example, a human over 75 years of age may be treated for sarcopenia, while a human under 30 years of age might not be identified as in need of treatment for sarcopenia. Alternatively, any of the mammals or subjects identified above may be excluded from the patient population in need of treatment for sarcopenia.
- A human subject may be identified as having sarcopenia or in need of treatment if (1) the subject is at least 25 years old and (2) his or her measured muscle mass and measured muscle function are two standard deviations or more below the mean value for healthy 25 year olds of the same gender and no alternative pathology has been identified to account for the reduced muscle mass and reduced muscle function. Preferably, a subject being treated for sarcopenia is at least 40 years old. More preferably, a subject being treated for sarcopenia is at least 50 years old. Most preferably, a subject being treated for sarcopenia is at least 60 years old. Alternatively, a subject may be identified as having sarcopenia or in need of treatment if (1) his or her gait speed is less than 1.0 m/s across a 4 m course and (2) he or she has an objectively measured low muscle mass, such as, for example, an appendicular mass relative to the square of height less than or equal to 7.23 kg/m2 for male subjects or less than or equal to 5.67 kg/m2 for female subjects.
- Any mammal that could develop neurodegenerative disorders may be treated by the methods herein described. Humans are a preferred mammal for treatment. Other mammals that may be treated include mice, rats, goats, sheep, cows, horses and companion animals, such as dogs or cats. A subject in need of treatment may be identified by the diagnosis of a neurodegenerative disorder.
- In the case of cancer, a mammal that could develop metastatic cancer may be treated by the methods herein described. Humans are a preferred mammal for treatment. Other mammals that may be treated include mice, rats, goats, sheep, cows, horses and companion animals, such as dogs or cats. A subject in need of treatment may be identified by the diagnosis of a cancer. Cancers which are particularly subject to metastasis include lung cancer, melanoma, colon cancer, renal cell carcinoma, prostate cancer, cancer of the cervix, bladder cancer, rectal cancer, esophageal cancer, liver cancer, mouth and throat cancer, multiple myeloma, ovarian cancer, and stomach cancer. Treatment may be of patients experiencing metastatic cancer. Treatment may also be administered to patients who have cancer, but prior to any identified metastasis, in order to prevent metastasis. A subject that receives administration of an anti-AGE antibody may be tested to determine if it has been effective to treat the cancer by examining the patient for the spread of the cancer to different parts of the body, particularly in lymph nodes. Administration of antibody and subsequent testing may be repeated until the desired therapeutic result is achieved.
- [69] AGE-RNAse is prepared by incubating RNAse in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-RNAse solution is dialyzed and the protein content is measured. Aluminum hydroxide or aluminum phosphate, as an adjuvant, is added to 100 pg of the AGE-RNAse. Formaldehyde or formalin is added as a preservative to the preparation. Ascorbic acid is added as an antioxidant. The vaccine also includes phosphate buffer to adjust the pH and glycine as a protein stabilizer.
- The composition is injected into a human subject subcutaneously. The subject's muscle mass is measured at'the time of injection to establish a baseline muscle mass value. The patient's muscle mass is measured again after one month. The one-month muscle mass value is compared to the baseline value. Additional injections are performed and additional muscle mass measurements are taken every month until the muscle mass measurement indicates no change, or an increase, from the baseline value.
- The same vaccine as described in Example 1 is injected into a human subject. The titer of antibodies to AGE-RNAse is determined by ELISA after two weeks. Additional injections are performed after three weeks and six weeks, respectively. Further titer determination is performed two weeks after each injection.
- AGE-hemoglobin is prepared by incubating human hemoglobin in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-hemoglobin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 1, except AGE-hemoglobin is substituted for AGE-RNAse.
- Administration is carried out as in Example 1, or as in Example 2. The number of senescent cells in the subject's adipose tissue is measured at the time of injection to establish a baseline number of senescent cells. The number of senescent cells in the subject's adipose tissue is measured again two months after injection and is compared to the baseline number of senescent cells. Additional injections are performed and additional senescent cell measurements are taken every two months to determine if the number of senescent cells in adipose tissue is increasing or decreasing, or if there is no change in the number of senescent cells in adipose tissue.
- AGE-human serum albumin is prepared by incubating human serum albumin in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-human serum albumin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 1, except AGE-human serum albumin is substituted for AGE-RNAse. Administration is carried out as in Example 1, or as in Example 2.
- To examine the effects of an anti-AGE antibody, the antibody was administered to the aged CD1(lCR) mouse (Charles River Laboratories), twice daily by intravenous injection, once a week, for three weeks (Days 1, 8 and 15), followed by a 10 week treatment-free period. The test antibody was a commercially available mouse anti-AGE antibody raised against carboxymethyl lysine conjugated with keyhole limpet hemocyanin. A control reference of physiological saline was used in the control animals.
- Mice referred to as “young” were 8 weeks old, while mice referred to as “old” were 88 weeks (±2 days) old. No adverse events were noted from the administration of the antibody. The different groups of animals used in the study are shown in Table 1.
-
TABLE 1 The different groups of animals used in the study Number of Animals Dose Level Main Treatment- Group Test (μg/gm/BID/ Study Free No. Material Mice week) Females Females 1 Saline young 0 20 — 2 Saline old 0 20 20 3 Antibody old 2.5 20 20 4 None old 0 20 pre 5 Antibody old 5.0 20 20 — = Not Applicable, Pre = Subset of animals euthanized prior to treatment start for collection of adipose tissue. - p16INK4A mRNA, a marker for senescent cells, was quantified in adipose tissue of the groups by Real Time-qPCR. The results are shown in Table 2. In the table ΔΔCt=ΔCt mean control Group (2)-ΔCt mean experimental Group (1 or 3 or 5); Fold Expression=2−ΔΔCt.
-
TABLE 2 P16INK4a mRNA quantified in adipose tissue Calculation (unadjusted Group 2 vs Group 1 Group 2 vs Group 3 Group 2 vs Group 5 to Group 4: 5.59) Group 2 Group 1 Group 2 Group 3 Group 2 Group 5 Mean ΔCt 5.79 7.14 5.79 6.09 5.79 7.39 ΔΔCt −1.35 −0.30 −1.60 Fold Expression 2.55 1.23 3.03 - The table above indicates that untreated old mice (Control Group 2) express 2.55-fold more p16ink4a mRNA than the untreated young mice (Control Group 1), as expected. This was observed when comparing Group 2 untreated old mice euthanized at end of recovery Day 85 to Group 1 untreated young mice euthanized at end of treatment Day 22. When results from Group 2 untreated old mice were compared to results from Group 3 treated old mice euthanized Day 85, it was observed that p16ink4a mRNA was 1.23-fold higher in Group 2 than in Group 3. Therefore, the level of p16ink4a mRNA expression was lower when the old mice were treated with 2.5 pg/gram/BID/week of antibody.
- [85] When results from Group 2 (Control) untreated old mice were compared to results from Group 5 (5 pg/gram) treated old mice euthanized Day 22, it was observed that p16ink4a mRNA was 3.03-fold higher in Group 2 (controls) than in Group 5 (5 μg/gram). This comparison indicated that the Group 5 animals had lower levels of p16ink4a mRNA expression when they were treated with 5.0 pg/gram/BID/week, providing p16Ink4a mRNA expression levels comparable to that of the young untreated mice (Group 1). Unlike Group 3 (2.5 pg/gram) mice that were euthanized at end of recovery Day 85, Group 5 mice were euthanized at end of treatment Day 22.
- These results indicate the antibody administration resulted in the killing of senescent cells.
- The mass of the gastrocnemius muscle was also measured, to determine the effect of antibody administration on a classic sign of aging, sarcopenia. The results are shown in Table 3. The results indicate that administration of the antibody increased muscle mass as compared to controls, but only at the higher dosage of 5.0 μg/gm/BID/week.
-
TABLE 3 Effect of antibody administration on mass of the gastrocnemius muscle Absolute weight of Weight relative Summary Gastrocnemius to body mass of Group Information Muscle Gastrocnemius Muscle 1 Mean 0.3291 1.1037 SD 0.0412 0.1473 N 20 20 2 Mean 0.3304 0.7671 SD 0.0371 0.1246 N 20 20 3 Mean 0.3410 0.7706 SD 0.0439 0.0971 N 19 19 5 Mean 0.4074 0.9480 SD 0.0508 0.2049 N 9 9 - These results demonstrate that administration of antibodies that bind to AGEs of a cell resulted in a reduction of cells expressing p16ink4a, a biomarker of senescence. The data show that reducing senescent cells leads directly to an increase in muscle mass in aged mice. These results indicate that the loss of muscle mass, a classic sign of sarcopenia, can be treated by administration of antibodies that bind to AGEs of a cell.
- 1. International Application Pub. No. WO 2009/143411 to Gruber (26 Nov. 2009).
- 2. U.S. Pat. No. 5,702,704 to Bucala (issued Dec. 30, 1997).
- 3. U.S. Pat. No. 6,380,165 to Al-Abed et al. (issued Apr. 30, 2002).
- 4. U.S. Pat. No. 6,387,373 to Wright etal. (issued May 14, 2002).
- 5. U.S. Pat. No. 4,217,344 to Vanlerberghe etal. (issued Aug. 12, 1980).
- 6. U.S. Pat. No. 4,917,951 to Wallach (issued Apr. 17, 1990).
- 7. U.S. Pat. No. 4,911,928 to Wallach (issued Mar. 27, 1990).
- 8. U.S. Patent Application Publication Pub. No. US 2010/226932 to Smith et al. (Sep. 9, 2010).
- 9. Baker, D. J. et al., “Clearance of p16ink4a -positive senescent cells delays ageing-associated disorders”, Nature, Vol. 479, pp. 232-236, (2011).
- 10. Ando, K. etal., “Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products during Aging in the Circulation”, Biochem. Biophys. Res. Commun., Vol. 258, 123, 125 (1999).
- 11. Lindsey, J. B. et al., “Receptor For Advanced Glycation End-Products (RAGE) and soluble RAGE (sRAGE): Cardiovascular Implications”, Diabetes Vascular Disease Research, Vol. 6(1), 7-14, (2009).
- 12. Bierhaus, A., “AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept”, Cardiovasc. Res., Vol. 37(3), 586-600 (1998).
- 13. Ahmed, E. K. et al., “Protein Modification and Replicative Senescence of WI-38 Human Embryonic Fibroblasts”, Aging Cells, Vol. 9, 252, 260 (2010).
- 14. Vlassara, H. et al., “Advanced Glycosylation Endproducts on Erythrocyte Cell Surface Induce Receptor-Mediated Phagocytosis by Macrophages”, J. Exp. Med., Vol. 166, 539, 545 (1987).
- 15. Vlassara, H. et al., “High-affinity-receptor-mediated Uptake and Degradation of Glucose-modified Proteins: A Potential Mechanism for the Removal of Senescent Macromolecules”, Proc. Natl. Acad. Sci. USA, Vol. 82, 5588, 5591 (1985).
- 16. Roll, P. et al., “Anti-CD20 Therapy in Patients with Rheumatoid Arthritis”, Arthritis & Rheumatism, Vol. 58, No. 6, 1566-1575 (2008).
- 17. Kajstura, J. et al., “Myocite Turnover in the Aging Human Heart”, Circ. Res., Vol. 107(11), 1374-86, (2010).
- 18. de Groot, K. et al., “Vascular Endothelial Damage and Repair in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis”, Arthritis and Rheumatism, Vol. 56(11), 3847, 3847 (2007).
- 19. Manesso, E. et al., “Dynamics of β-Cell Turnover: Evidence for β-Cell Turnover and Regeneration from Sources of β-Cells other than β-cell Replication in the HIP Rat”, Am. J. Physiol. Endocrinol Metab., Vol. 297, E323, E324 (2009).
- 20. Kirstein, M. et al., “Receptor-specific Induction of Insulin-like Growth Factor I in Human Monocytes by Advanced Glycosylation End Product-modified Proteins”, J. Clin. Invest., Vol. 90, 439, 439-440 (1992). 316
- 21. Murphy, J. F., “Trends in cancer immunotherapy”, Clinical Medical Insights: Oncology, Vol. 14(4), 67-80 (2010).
- 22. Flint, S. J. et al., “Principles of Virology”, ASM Press (2000).
- 23. Buskas, T. et al., “Immunotherapy for Cancer: Synthetic Carbohydrate-based Vaccines”, Chem. Commun., Vol. 28(36), 5335-349 (2009).
- 24. Beier, K. C. etal., “Master Switches of T-cell Differentiation”, Eur. Respir. J., Vol. 29, 804-12 (2007).
- 25. Schmidlin H. et al., “New Insights in the Regulation of Human B Cell Differentiation”, Trends Immuno., Vol. 30(6), 277-85 (2009).
- 26. Vogel, F. R. et aL, “A compendium of vaccine adjuvants and excipients”, Pharmaceutical Biotechnology, Vol. 6, pp. 141-228 (1995).
- 27. Coler, R. N. et al., “Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant”, PLoS ONE, Vol. 6(1): e16333 (2011).
- 28. Cheadle, E. J. et al., “Bugs as Drugs for Cancer”, Immunology, Vol. 107, 10-19 (2002).
- 29. Jiang, Z-H. et al. “Synthetic vaccines: the role of adjuvants in immune targeting”, Current Medicinal Chemistry, Vol. 10(15), pp. 1423-39 (2003).
- 30. Virella, G. et al., “Autoimmune Response to Advanced Glycosylation End-Products of Human LDL”, Journal of Lipid Research, Vol. 44, 487-493 (2003).
- 31. Ameli, S. et al., “Effect of Immunization With Homologous LDL and Oxidized LDL on Early Atherosclerosis in Hypercholesterolemic Rabbits”, Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 16, 1074 (1996).
- 32. “Vaccine Excipient & Media Summary”, available online at www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf (The Pink Book, Epidemiology and Prevention of Vaccine-Preventable Diseases, 12th Ed. Second Printing, September 2013).
- 33. “Sarcopenia”, available online at en.wikipedia.org/wiki/Sarcopenia (Nov. 14, 2014).
- 34. “What is sarcopenia?”, available online at www.iofbonehealth.org/what-sarcopenia (2014).
- 35. Bland, W., “Sarcopenia with aging”, available online at www.webmd.com/healthy-aging/sarcopenia-with-aging (Aug. 3, 2014).
- 36. “Keyhole limpet hemocyanin”, available online at en.wikipedia.org/wiki/Keyhole_limpet_hemocyanin (Apr. 18, 2014).
- 37. “CML-BSA Product Data Sheet”, available online at www.cellbiolabs.com/sites/default/files/STA-314-cml-bsa.pdf (2010).
- 38. “CML (N-epsilon-(Carboxymethyl)Lysine) Assays and Reagents”, available online at www.cellbiolabs.com/cml-assays (Accessed on Dec. 15, 2014).
- 39. Cruz-Jentoft, A. J. et al., “Sarcopenia: European consensus on definition and diagnosis”, Age and Ageing, Vol. 39, pp. 412-423 (Apr.13, 2010).
- 40. Rolland, Y. et al., “Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives”, J. Nutr. Health Aging, Vol. 12(7), pp. 433-450 (2008).
- 41. Mera, K. et al., “An autoantibody against Nε-(carboxyethyl)lysine (CEL): Possible involvement in the removal of CEL-modified proteins by macrophages”, Biochemical and Biophysical Research Communications, Vol. 407, pp. 420-425 (Mar. 12, 2011).
- 42. Reddy, S. et al., “Nε-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins”, Biochemistry, Vol. 34, pp. 10872-10878 (Aug. 1, 1995).
- 43. Naylor, R. M. et al., “Senescent cells: a novel therapeutic target for aging and age-related diseases”, Clinical Pharmacology & Therapeutics, Vol. 93(1), pp.105-116 (Dec. 5, 2012).
- 44. Katcher, H. L., “Studies that shed new light on aging”, Biochemistry (Moscow), Vol. 78(9), pp. 1061-1070 (2013).
- 45. Fielding, R. A., et al., “Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences”, Journal of the American Medical Directors Association, Vol. 12(4), pp. 249-256 (May 2011).
- 46. Fu, M-X., et al., “The advanced glycation end product, Nε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions”, The Journal of Biological Chemistry, Vol. 271, No. 17, pp. 9982-9986 (Apr. 26, 1996).
Claims (24)
1. A method of treating or preventing a disease or disorder associated with cellular senescence, comprising immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell,
wherein the disease or disorder is selected from the group consisting of sarcopenia, inflammation, the onset of cataracts, the onset of loss of adipose tissue, the onset of lordokyphosis, auto-immune disorders, and neurodegenerative disorders.
2. A method of treating a subject with a disease or disorder associated with cellular senescence, comprising:
administering a first vaccine comprising a first AGE antigen; and
administering a second vaccine comprising a second AGE antigen;
wherein the second AGE antigen is different from the first AGE antigen and
the disease or disorder associated with cellular senescence does not comprise sarcopenia.
3. (canceled)
4. The method of claim 1 , wherein the immunizing comprises administering a vaccine comprising an AGE antigen.
5. The method of claim 4 , wherein the vaccine comprises
(a) the AGE antigen,
(b) an adjuvant,
(c) optionally, a preservative, and
(d) optionally, an excipient.
6. The method of claim 1 , wherein the subject is selected from the group consisting of humans, goats, sheep, cows, horses, dogs and cats.
7. The method of claim 6 , wherein the subject is a human.
8. The method of claim 4 , wherein the vaccine is administered in an amount effective to cause the immune system to produce antibodies to cells having AGE-modified proteins or peptides.
9. The method of claim 1 , wherein the subject does not have diabetes.
10. The method of claim 4 , wherein the AGE antigen comprises, an AGE-modified protein or peptide selected from the group consisting of AGE-RNAse, AGE-human hemoglobin, AGE-human serum albumin, AGE-low density lipoprotein, AGE-collagen IV, AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-I and II, AGE-hemoglobin, AGE-Na+/K+-ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-β-N-acetyl hexokinase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE-β2-microglobulin, AGE-sorbitol dehydrogenase, AGE-ai-antitrypsin, AGE-carbonate dehydratase, AGE-hexokinase, AGE-apo C-I, AGE-keyhole limpet hemocyanin (AGE-KLH) and mixtures thereof.
11. The method of claim 4 , wherein the AGE antigen comprises at least one protein or peptide that exhibits AGE modifications selected from the group consisting of carboxymethyllysine, carboxyethyllysine, pentosidine, pyrraline, FFI, AFGP, and ALI.
12. The method of claim 11 , wherein the AGE antigen comprises a carboxymethyllysine-modified protein or peptide.
13. The method of claim 4 , wherein
the vaccine is sterile, and
the vaccine is in unit dosage form.
14. The method of claim 4 , wherein
the vaccine is sterile, and
the vaccine is in multidosage form.
15-35. (canceled)
36. The method of claim 1 , further comprising testing the subject to determine if the disease or disorder associated with cellular senescence has been ameliorated, and
repeating the immunizing, if necessary.
37. (canceled)
38. (canceled)
39. A method of treating or preventing atherosclerosis associated with cellular senescence, comprising immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell,
wherein the immunizing comprises administering a vaccine comprising an AGE antigen, and
the AGE antigen is not AGE-low density lipoprotein.
40. The method of claim 39 , wherein the AGE antigen comprises an AGE-modified protein or peptide selected from the group consisting of AGE-RNAse, AGE-human human hemoglobin, AGE-human serum albumin, AGE-collagen IV, AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-I and II, AGE-hemoglobin, AGE-Na+/K+-ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-β-N-acetyl hexokinase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE-β2-microglobulin, AGE-sorbitol dehydrogenase, AGE-α1-antitrypsin, AGE-carbonate dehydratase, AGE-hexokinase, AGE-apo C-l, AGE-keyhole limpet hemocyanin (AGE-KLH) and mixtures thereof.
41. The method of claim 39 , wherein the AGE antigen comprises a carboxymethyllysine-modified protein or peptide.
42. The method of claim 39 , further comprising testing the subject to determine if the atherosclerosis associated with cellular senescence has been ameliorated, and
repeating the immunizing, if necessary.
43. The method of claim 2 , wherein the first AGE antigen and the second AGE antigen each independently comprises an AGE-modified protein or peptide selected from the group consisting of AGE-RNAse, AGE-human hemoglobin, AGE-human serum albumin, AGE-low density lipoprotein, AGE-collagen IV, AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-I and II, AGE-hemoglobin, AGE-Na+K+-ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-6-N-acetyl hexokinase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE-β2-microglobulin, AGE-sorbitol dehydrogenase, AGE-ai-antitrypsin, AGE-carbonate dehydratase, AGE-hexokinase, AGE-apo C-I, AGE-keyhole limpet hemocyanin (AGE-KLH) and mixtures thereof.
44. The method of claim 2 , wherein the first AGE antigen comprises a carboxymethyllysine-modified protein or peptide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/544,636 US20220160869A1 (en) | 2016-06-23 | 2021-12-07 | Vaccines for use in treating various diseases and disorders |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2016/039076 WO2017222535A1 (en) | 2016-06-23 | 2016-06-23 | Vaccines for use in treating various diseases and disorders |
US201816311149A | 2018-12-18 | 2018-12-18 | |
US17/544,636 US20220160869A1 (en) | 2016-06-23 | 2021-12-07 | Vaccines for use in treating various diseases and disorders |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/039076 Continuation WO2017222535A1 (en) | 2016-06-23 | 2016-06-23 | Vaccines for use in treating various diseases and disorders |
US16/311,149 Continuation US11213585B2 (en) | 2016-06-23 | 2016-06-23 | Vaccines for use in treating various diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220160869A1 true US20220160869A1 (en) | 2022-05-26 |
Family
ID=56409172
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/311,149 Active 2036-08-18 US11213585B2 (en) | 2016-06-23 | 2016-06-23 | Vaccines for use in treating various diseases and disorders |
US17/544,636 Pending US20220160869A1 (en) | 2016-06-23 | 2021-12-07 | Vaccines for use in treating various diseases and disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/311,149 Active 2036-08-18 US11213585B2 (en) | 2016-06-23 | 2016-06-23 | Vaccines for use in treating various diseases and disorders |
Country Status (4)
Country | Link |
---|---|
US (2) | US11213585B2 (en) |
EP (1) | EP3475306A1 (en) |
JP (3) | JP2019518763A (en) |
WO (1) | WO2017222535A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
US11542324B2 (en) | 2017-04-13 | 2023-01-03 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US11833202B2 (en) | 2016-02-19 | 2023-12-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) |
US11873345B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Product and method for treating sarcopenia |
US11872269B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Method and composition for treating sarcopenia |
US11958900B2 (en) | 2016-04-15 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2616728T3 (en) | 2008-05-23 | 2017-06-14 | Siwa Corporation | Procedures and compositions to facilitate regeneration |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
ES2908203T3 (en) | 2014-09-19 | 2022-04-28 | Siwa Corp | Anti-aging antibodies for the treatment of inflammation and autoimmune disorders |
JP2019518763A (en) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | Vaccines for use in the treatment of various diseases and disorders |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
WO2020023532A1 (en) * | 2018-07-23 | 2020-01-30 | Siwa Corporation | Methods and compositions for treating chronic effects of radiation and chemical exposure |
US20220267374A1 (en) * | 2019-07-29 | 2022-08-25 | Juntendo Educational Foundation | Immunity inducer and pharmaceutical composition for preventing or treating aging-related diseases |
WO2021247397A2 (en) * | 2020-06-04 | 2021-12-09 | Siwa Corporation | Methods and compositions for enhancing the immune system |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012135616A1 (en) * | 2011-03-31 | 2012-10-04 | Siwa Corporation | Vaccination against advanced glycation end-products |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4900747A (en) | 1984-03-19 | 1990-02-13 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
US5811075A (en) | 1984-03-19 | 1998-09-22 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
JP2644767B2 (en) | 1986-09-12 | 1997-08-25 | ザ ロックフェラー ユニバーシティ | Methods and agents for removing advanced glycosylation end products |
US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20080063603A1 (en) | 1990-04-02 | 2008-03-13 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US20040208826A1 (en) | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
IN172208B (en) | 1990-04-02 | 1993-05-01 | Sint Sa | |
US6372249B1 (en) | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
US5624804A (en) | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
DE69214672T2 (en) | 1991-12-20 | 1997-04-03 | Technomed Medical Systems | SOUNDWAVE EMITTING, THERMAL EFFECTS AND CAVITATION EFFECTS DEVICE FOR ULTRASONIC THERAPY |
WO1994000592A1 (en) | 1992-06-26 | 1994-01-06 | Exocell, Inc. | Monoclonal antibodies against glycated low density lipoprotein |
US5620479A (en) | 1992-11-13 | 1997-04-15 | The Regents Of The University Of California | Method and apparatus for thermal therapy of tumors |
US5518720A (en) | 1992-12-30 | 1996-05-21 | Exocell, Inc. | Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
JPH09500102A (en) | 1993-04-28 | 1997-01-07 | ウォーセスター ファウンデーション フォー エクスペリメンタル バイオロジー | Cell-directed dissolution pore forming agent |
JPH09511492A (en) | 1994-02-03 | 1997-11-18 | ザ ピコワー インスティテュート フォア メディカル リサーチ | Compositions and methods for advanced glycosylation end product mediated modulation of amyloidosis |
US6410598B1 (en) | 1994-02-03 | 2002-06-25 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
US5744318A (en) | 1994-12-30 | 1998-04-28 | Alteon Inc. | Monoclonal antibody for the detection of advanced glycosylation endproducts in biological samples |
DE69531311T2 (en) | 1994-12-30 | 2004-04-22 | Alteon Inc. | MONOCLONAL ANTIBODIES SPECIFIC FOR END PRODUCTS OF ADVANCED GLYCOSYLATION IN BIOLOGICAL SAMPLES |
US6176842B1 (en) | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
WO1997007803A1 (en) | 1995-08-25 | 1997-03-06 | Case Western Reserve University | Process for detecting pentosidine and for assessing the biological age of a biological sample |
JP3579549B2 (en) | 1995-10-24 | 2004-10-20 | 株式会社トクヤマ | Use as a marker for diabetes or diabetic complications |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US5664570A (en) | 1996-02-20 | 1997-09-09 | Svc | Apparatus for applying high-intensity ultrasonic waves to a target volume within a human or animal body |
US5908925A (en) | 1996-06-27 | 1999-06-01 | Exocell, Inc. | Genetically engineered immunoglobulins with specificity for glycated albumin |
US5984882A (en) | 1996-08-19 | 1999-11-16 | Angiosonics Inc. | Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US6245318B1 (en) | 1997-05-27 | 2001-06-12 | Mallinckrodt Inc. | Selectively binding ultrasound contrast agents |
US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
CN1270637A (en) | 1997-08-08 | 2000-10-18 | 华盛顿大学 | Isolation of a novel senescence-factor gene, P23 |
US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
US6896659B2 (en) | 1998-02-06 | 2005-05-24 | Point Biomedical Corporation | Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility |
JP4016304B2 (en) | 1998-02-26 | 2007-12-05 | 日本油脂株式会社 | Monoclonal antibody, hybrid cell, and method for producing monoclonal antibody |
JP2002517224A (en) | 1998-06-09 | 2002-06-18 | アルテオン インコーポレーテッド | Monoclonal antibodies specific for advanced glycosylation end products from guanidino groups in biological samples |
US6753150B2 (en) | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
EP1121454B1 (en) | 1998-10-06 | 2007-11-14 | The Trustees of Columbia University in the City of New York | Extracellular novel rage binding protein (en-rage) and uses thereof |
US6309355B1 (en) | 1998-12-22 | 2001-10-30 | The Regents Of The University Of Michigan | Method and assembly for performing ultrasound surgery using cavitation |
JP2002538170A (en) | 1999-03-02 | 2002-11-12 | セントコール, インコーポレイテッド | Anti-TNFα antibodies in the treatment of asthma |
US6067859A (en) | 1999-03-04 | 2000-05-30 | The Board Of Regents, The University Of Texas System | Optical stretcher |
CN100340575C (en) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
EP1307219A4 (en) | 1999-08-13 | 2005-04-06 | Univ Columbia | Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
WO2001018060A1 (en) | 1999-09-08 | 2001-03-15 | Toray Industries, Inc. | Materials for extracorporeal circulation, adsorbents for diabetic complication factors, containers for eliminating diabetic complication factors and method of eliminating diabetic complication factors |
US6853864B2 (en) | 2000-02-02 | 2005-02-08 | Catholic University Of America, The | Use of electromagnetic fields in cancer and other therapies |
SI2857516T1 (en) | 2000-04-11 | 2017-09-29 | Genentech, Inc. | Multivalent antibodies and uses therefor |
EP1283728A2 (en) | 2000-05-23 | 2003-02-19 | Amersham Health AS | Contrast agents |
NO312338B1 (en) | 2000-08-25 | 2002-04-29 | Gunnar Myhr | Device for selective cell or virus destruction in a living organism |
CN2445326Y (en) | 2000-10-09 | 2001-08-29 | 刘永详 | Immune analysis device for assaying saccharified protein |
US6676963B1 (en) | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
US7481781B2 (en) | 2000-11-17 | 2009-01-27 | Gendel Limited | Ultrasound therapy |
US6821274B2 (en) | 2001-03-07 | 2004-11-23 | Gendel Ltd. | Ultrasound therapy for selective cell ablation |
US7347855B2 (en) | 2001-10-29 | 2008-03-25 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
EP1362223B1 (en) | 2001-01-03 | 2008-05-21 | Ultrashape Inc. | Non-invasive ultrasonic body contouring |
ATE283481T1 (en) | 2001-03-22 | 2004-12-15 | Hoffmann La Roche | METHOD FOR FINDING REAGENTS AND SOLID PHASE COMPONENTS IN SPECIFIC BINDING ASSAY, FREE OF ADVANCED GLYCOSYLATION END PRODUCTS |
WO2003008446A1 (en) | 2001-07-19 | 2003-01-30 | Mitsubishi Pharma Corporation | Polypeptides relating to signal transfer of advanced glycation end product receptor |
JP4012722B2 (en) | 2001-11-22 | 2007-11-21 | 株式会社トランスジェニック | Antibodies against carboxymethylated peptides |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
CA2492964C (en) | 2002-07-24 | 2012-07-17 | Qlt Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
EP1575513A4 (en) | 2002-08-16 | 2007-04-04 | Wyeth Corp | Compositions and methods for treating rage-associated disorders |
US20070128117A1 (en) | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
US7700307B2 (en) | 2003-03-08 | 2010-04-20 | Auvation Limited | Mitochondrial stress-70 protein markers for colorectal cancer |
US20060122543A1 (en) | 2003-07-31 | 2006-06-08 | Woodwelding Ag | Method for promoting tissue regeneration on wound surfaces as device and treatment instrument or implant for carrying out method |
US7358226B2 (en) | 2003-08-27 | 2008-04-15 | The Regents Of The University Of California | Ultrasonic concentration of drug delivery capsules |
EP2213310A1 (en) | 2004-01-20 | 2010-08-04 | Sunnybrook and Women's College Health Sciences Centre | High frequency ultrasound imaging using contrast agents |
JP2007523908A (en) | 2004-02-17 | 2007-08-23 | ダイナミス セラピューティクス インコーポレイテッド | Fructosamine 3 kinase and collagen and elastin formation |
EP1771565B1 (en) | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivatives |
AP2007003869A0 (en) | 2004-08-03 | 2007-02-28 | Transtech Pharma Inc | Rage fusion proteins and methods of use |
GB0422525D0 (en) | 2004-10-11 | 2004-11-10 | Luebcke Peter | Dermatological compositions and methods |
GT200600031A (en) | 2005-01-28 | 2006-08-29 | ANTI-BETA ANTIBODY FORMULATION | |
US7846100B2 (en) | 2005-03-03 | 2010-12-07 | Bracco International Bv | Medical imaging system based on a targeted contrast agent |
JP2006249015A (en) | 2005-03-11 | 2006-09-21 | Mochida Pharmaceut Co Ltd | Cellular senescence inhibitor |
KR20070094950A (en) | 2005-04-05 | 2007-09-27 | 가부시끼가이샤 제이엠에스 | Antibody reactive specifically to age derived from 3,4-dge |
US20070225242A1 (en) | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007027584A2 (en) | 2005-08-30 | 2007-03-08 | University Of Virginia Patent Foundation | Deposit contrast agents and related methods thereof |
US20070065415A1 (en) | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
US20070083120A1 (en) | 2005-09-22 | 2007-04-12 | Cain Charles A | Pulsed cavitational ultrasound therapy |
US20070078290A1 (en) | 2005-09-30 | 2007-04-05 | Esenaliev Rinat O | Ultrasound-based treatment methods for therapeutic treatment of skin and subcutaneous tissues |
US7766833B2 (en) | 2005-11-23 | 2010-08-03 | General Electric Company | Ablation array having independently activated ablation elements |
JP4779115B2 (en) | 2005-12-16 | 2011-09-28 | 国立大学法人東北大学 | Postoperative prognostic method for early lung cancer |
US20100226932A1 (en) | 2006-02-22 | 2010-09-09 | Novavax, Inc. | Adjuvant and Vaccine Compositions |
LT2676967T (en) | 2006-02-28 | 2019-09-10 | Biogen Ma Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
US9056905B2 (en) | 2007-05-21 | 2015-06-16 | Alderbio Holdings Llc | Antibodies to TNF-α and use thereof |
US20100249038A1 (en) | 2007-06-12 | 2010-09-30 | Board Of Regents, University Of Texas System | Antagonists of the receptor for advanced glycation end-products (rage) |
KR101361355B1 (en) | 2007-06-14 | 2014-02-12 | 갈락티카 파마슈티칼스, 인크. | Rage fusion proteins |
JP2007277263A (en) | 2007-07-13 | 2007-10-25 | Transgenic Inc | Antibody to carboxymethylated protein |
US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
US7751057B2 (en) | 2008-01-18 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Magnetomotive optical coherence tomography |
DE102008009461A1 (en) | 2008-02-15 | 2009-08-20 | Beiersdorf Ag | Reducing the wrinkle, comprises applying a cosmetic preparation on the skin to be treated and subsequently working up by means of an ultrasonic applicator |
CA2723219A1 (en) | 2008-05-09 | 2009-11-12 | Abbott Gmbh & Co. Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
ES2616728T3 (en) | 2008-05-23 | 2017-06-14 | Siwa Corporation | Procedures and compositions to facilitate regeneration |
JP5229473B2 (en) | 2008-06-04 | 2013-07-03 | 財団法人ヒューマンサイエンス振興財団 | Ultrasound medical equipment |
WO2010005531A2 (en) | 2008-06-30 | 2010-01-14 | The Johns Hopkins University | Methods for the detection of advanced glycation endproducts and markers for disease |
WO2011035104A1 (en) | 2009-09-17 | 2011-03-24 | Sanuwave, Inc. | Methods and devices for cleaning and sterilization with shock waves |
US20110070227A1 (en) | 2009-09-18 | 2011-03-24 | Anna-Marie Novotney-Barry | Treatment of Autoimmune and Inflammatory Diseases |
WO2011053322A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
WO2011101039A1 (en) | 2010-02-22 | 2011-08-25 | Universite Pierre Et Marie Curie (Paris 6) | Apparatus for the treatment of brain affections and method implementing thereof |
KR101351181B1 (en) | 2010-05-11 | 2014-01-14 | 가천대학교 산학협력단 | Method for inhibiting cell death induction by inhibiting synthesis or secretion of AGE-albumin in mononuclear phagocyte system |
ES2725852T3 (en) | 2010-09-27 | 2019-09-27 | Siwa Corp | Selective removal of AGE modified cells for the treatment of atherosclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
UA112434C2 (en) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | ANTIGENCY BINDING SPECIFICALLY Binds to ALL |
US9452302B2 (en) | 2011-07-10 | 2016-09-27 | Guided Therapy Systems, Llc | Systems and methods for accelerating healing of implanted material and/or native tissue |
US8954155B2 (en) | 2011-09-19 | 2015-02-10 | Biotalk Technologies Inc | Apparatus and method for rejuvenating skin |
US9422365B2 (en) | 2011-09-23 | 2016-08-23 | Julius-Maximilians-Universität Würzburg | Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site |
US20140322216A1 (en) | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
KR101939401B1 (en) | 2011-11-10 | 2019-01-16 | 가천대학교 산학협력단 | Composition for preventing or treating ischemic cardiac diseases comprising inhibiting agent for synthesis or secretion of AGE-albumin of mononuclear phagocyte as active ingredient |
TWI557112B (en) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | Inhibitors of beta-secretase |
US20130288980A1 (en) | 2012-04-02 | 2013-10-31 | Buck Institute For Research On Aging | Targeting senescent and cancer cells for selective killing by interference with foxo4 |
EP2742935A1 (en) | 2012-12-14 | 2014-06-18 | Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH | SERF2 for the treatment of atrophy and for increasing cell growth |
US20160017021A1 (en) | 2013-03-06 | 2016-01-21 | Protalix Ltd. | TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME |
US20140257262A1 (en) | 2013-03-11 | 2014-09-11 | Alexandre Carpentier | Interstitial ultrasonic disposable applicator and method for tissue thermal conformal volume ablation and monitoring the same |
EP3094350B1 (en) | 2014-01-15 | 2020-03-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cartilage targeting agents and their use |
EP3096824A1 (en) | 2014-01-24 | 2016-11-30 | Cole Research&Design, Inc. | Oral suction device |
SG10201805670QA (en) | 2014-01-28 | 2018-08-30 | Buck Inst Res Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
ES2908203T3 (en) * | 2014-09-19 | 2022-04-28 | Siwa Corp | Anti-aging antibodies for the treatment of inflammation and autoimmune disorders |
EP3207062A1 (en) | 2014-10-16 | 2017-08-23 | The Broad Institute Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
KR20180056689A (en) | 2015-10-13 | 2018-05-29 | 시와 코퍼레이션 | Anti-AGE antibody and its use |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
WO2018191718A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
ES2770787T3 (en) | 2016-02-19 | 2020-07-03 | Siwa Corp | Method and composition for treating cancer, destroying metastatic cancer cells and preventing cancer metastasis using advanced glycation end-product antibody (AGE) |
US10981021B2 (en) | 2016-03-11 | 2021-04-20 | Carthera | Method for transiently disrupting a region of the blood-brain barrier of a human |
WO2017181116A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
JP2019518763A (en) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | Vaccines for use in the treatment of various diseases and disorders |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
JP2020521117A (en) | 2017-05-04 | 2020-07-16 | シワ コーポレーション | Antibody for advanced glycation end products |
WO2020023532A1 (en) | 2018-07-23 | 2020-01-30 | Siwa Corporation | Methods and compositions for treating chronic effects of radiation and chemical exposure |
WO2020041625A1 (en) | 2018-08-23 | 2020-02-27 | Siwa Corporation | Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells |
EP4143238A1 (en) | 2020-05-01 | 2023-03-08 | Siwa Corporation | Methods of treating infections |
-
2016
- 2016-06-23 JP JP2018566505A patent/JP2019518763A/en active Pending
- 2016-06-23 EP EP16738275.3A patent/EP3475306A1/en active Pending
- 2016-06-23 WO PCT/US2016/039076 patent/WO2017222535A1/en unknown
- 2016-06-23 US US16/311,149 patent/US11213585B2/en active Active
-
2021
- 2021-09-24 JP JP2021155024A patent/JP2022000456A/en active Pending
- 2021-12-07 US US17/544,636 patent/US20220160869A1/en active Pending
-
2022
- 2022-10-20 JP JP2022168035A patent/JP2023011685A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012135616A1 (en) * | 2011-03-31 | 2012-10-04 | Siwa Corporation | Vaccination against advanced glycation end-products |
Non-Patent Citations (1)
Title |
---|
Reddy et al., Biochem. 34;10872-10878 (1995) (Year: 1995) * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11873345B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Product and method for treating sarcopenia |
US11872269B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Method and composition for treating sarcopenia |
US11833202B2 (en) | 2016-02-19 | 2023-12-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) |
US11958900B2 (en) | 2016-04-15 | 2024-04-16 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
US11542324B2 (en) | 2017-04-13 | 2023-01-03 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Also Published As
Publication number | Publication date |
---|---|
WO2017222535A1 (en) | 2017-12-28 |
EP3475306A1 (en) | 2019-05-01 |
US11213585B2 (en) | 2022-01-04 |
JP2019518763A (en) | 2019-07-04 |
JP2023011685A (en) | 2023-01-24 |
US20190328873A1 (en) | 2019-10-31 |
JP2022000456A (en) | 2022-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11213585B2 (en) | Vaccines for use in treating various diseases and disorders | |
US11872269B2 (en) | Method and composition for treating sarcopenia | |
US10925937B1 (en) | Vaccines for use in treating juvenile disorders associated with inflammation | |
US20220175916A1 (en) | Methods and compositions for treating chronic effects of radiation and chemical exposure | |
US10961321B1 (en) | Methods and compositions for treating pain associated with inflammation | |
JP6301995B2 (en) | Secreted aP2 and methods for inhibiting the same | |
US20210253737A1 (en) | Methods and compositions for treating disease-related cachexia | |
WO2012135616A1 (en) | Vaccination against advanced glycation end-products | |
US20140294849A1 (en) | Compositions and uses | |
US20120321694A1 (en) | Compositions and uses | |
WO2022093195A1 (en) | Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens | |
JP6093304B2 (en) | Immunogenic compositions and methods for treating neurological disorders | |
Chang et al. | Caveolin‐1 secreted from adipose tissues and adipocytes functions as an adipogenesis enhancer | |
Osborne et al. | Intrahippocampal administration of a domain antibody that binds aggregated amyloid-β reverses cognitive deficits produced by diet-induced obesity | |
Yang et al. | Activation of the niacin receptor HCA2 reduces demyelination and neurofilament loss, and promotes functional recovery after spinal cord injury in mice | |
WO2015165980A2 (en) | Treatment and prevention of alzheimer's disease (ad) | |
Gruber | METHOD AND COMPOSITION FOR TREATING SARCOPENIA-Patent Information | |
Reiss et al. | Tau and Alzheimer’s Disease: Molecular Mechanisms and Treatment Approaches | |
JP6372931B2 (en) | Diabetes medicine | |
Ferrucci et al. | P1‐274: EEG and cognitive effects of transcranial direct current stimulation (tDCS) in patients with Alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |